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1 Introduction 
For a long time, peritoneal metastasis (PM) has been considered to be a terminal 
clinical condition without any possible curative therapeutic approach (Weber et 
al., 2012). Patients suffering from different cancer types combined with PM were 
only treated with palliative intravenous systemic chemotherapy; the results were 
limited, for example with a median survival period of 5-7 months in patients with 
PM of colorectal origin (Jayne et al., 2002). Gradually, as new chemotherapeutic 
drugs and biological agents were developed, treatment options of PM have been 
enlarged. However, the median survival rates of 16 months for colorectal cancer 
(Franko et al., 2016), 7 – 10 months for gastric cancer (Rivera et al., 2007), 4 – 
10 months for ovarian cancer (Hanker et al., 2012) and 6 – 12 months for 
peritoneal mesothelioma (Chua et al., 2009), are still not satisfying. 
In 1996, Sugarbaker suggested to overthink the point of view upon current 
understanding of cancer spreading, establishing the idea of considering PM as a 
locally advanced disease, if metastases in other organs could be excluded 
(Sugarbaker, 1996). Thus, in the last three decades, a new multimodal approach 
to deal with PM has been established, combining Complete Cytoreductive 
Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and 
possibly systemic chemotherapy. The idea is to remove the entire visible tumor 
tissue and then fill the abdominal cavity with a heated chemotherapeutic solution 
in order to erase microscopic tumoral remains, which are still present after 
surgery and are responsible for the relapse of PM (Losa et al., 2014, Sugarbaker, 
2016). There is a consens that CRS and HIPEC should only be offered to highly 
selected patients (Weber et al., 2012). The decision for applying this combination 
takes into consideration the extent of disease, as measured by the Peritoneal 
Cancer Index (PCI), the tumor type and the general condition of the patient, 
quantified by means of the Karnofsky performance status scale (Beckert et al., 
2016). Diffuse small bowel infiltration has to be regarded as a contraindication 
due to the fact that, through CRS, a too short vital small bowel segment would be 
left, which is incompatible with life (Marmor et al., 2016). In addition to that, this 
treatment strategy is hampered by significant risks and side effects (Gill et al., 
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2011). Despite these limitations, in clinical practice, CRS + HIPEC is commonly 
performed and is established as the standard therapeutic approach to selected 
patients with PM from various original tumor locations (Losa et al., 2014, de Cuba 
et al., 2013, Sugarbaker, 2016). 
In the past, chemotherapy has been exclusively administered intravenously. 
However, it has been shown, that loco-regional delivery is associated with a 
better therapeutic ratio, namely a high local drug concentration and a lower 
systemic exposure resulting in less toxicity (Markman, 2003). However, classical 
methods for delivering intracavitary chemotherapy are hampered by 
pharmacological limitations (Ceelen and Flessner, 2010). These limitations 
include in particular a poor penetration into the tissue and an inhomogeneous 
distribution pattern (Dedrick and Flessner, 1997). A particular problem is the 
elevated interstitial pressure in tumor tissue, which counteracts the effective, 
deep penetration of therapeutic drugs into the tumor nodules (Heldin et al., 2004). 
In the last twenty years, many efforts have been made to develop new strategies 
for treating PM of various origins. In order to overcome these above mentioned 
limitations, a new drug delivery system into the peritoneal cavity has been 
proposed (Reymond et al., 2000), called Pressurized intraperitoneal aerosol 
chemotherapy (PIPAC). PIPAC is a new innovative approach to treat PM more 
effectively by administering a pressurized, chemotherapeutic drug containing 
aerosol into the abdominal cavity. The rationale for this approach is to use the 
physical characteristics of gas and pressure and closed abdomen physical laws 
to obtain a more homogeneous drug distribution and a deeper drug penetration 
into tumoral tissue. Several experimental studies document an increased drug 
penetration into tissues when a positive hydrostatic pressure is applied, including 
studies in vitro (Haidara et al 2017), in the rodent (Jacquet et al., 1996, Esquis et 
al., 2006), in the swine (Facy et al., 2012, Solass et al., 2012b), ex vivo (Solass 
et al., 2012a) and in vivo (Solass et al., 2012b). 
Moreover, it has been shown that aerosolizing of a therapeutic drug into a 
capnoperitoneum improves homogeneity of drug distribution as compared to 
intraperitoneal lavage with a liquid solution (Solass et al., 2012b, Solass et al., 
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2012a, Sanchez-Garcia et al., 2014, Padilla-Valverde et al., 2016). Presence of 
drug in tissue has been documented in all compartments of the abdomen 
(Khosrawipour et al., 2016c). However, this homogeneity is still not ideal, as 
demonstrated ex vivo (Khosrawipour et al., 2016b, Khosrawipour et al., 2016a) 
and in the post-mortem swine model (Khosrawipour et al., 2016c).  
It must be noted, that in all models above, measurements were performed under 
static conditions: only the result of application, as determined by tissue 
concentration or penetration depth at the end of the period of exposition, was 
measured. This is obviously a significant limitation since aerosol distribution is 
depending upon time. Due to gravitation forces, any aerosol is expected to 
sediment after a given period of time. In the present work, a new dynamic, 
thermographic model, analyzing the injection behavior and the consecutive 
spatial distribution of the aerosol over time, is introduced with the purpose of filling 
this particular gap in PIPAC research.   
At present, a CE-certified device, the Capnopen® (Capnomed GmbH 
Villingendorf, Germany) is used as standard in the operational setting for 
nebulizing the drug containing solution into the abdominal cavity. Various 
publications have demonstrated, that the spatial distribution of the administered 
aerosol is still not ideally homogenous (Khosrawipour et al., 2016c, Khosrawipour 
et al., 2016b) and droplet size still varies to a considerable extent (Gohler et al., 
2016) It might be interesting to examine the technical properties and the spraying 
behavior of the Capnopen® of the next generation (Prototype4). In the present 
work, these two generations of nebulizers are compared considering the spatial 
distribution of the aerosol. 
Until now, many different preclinical studies have been performed in order to 
optimize PIPAC technology. In doing so, different models, such as plastic boxes 
(Khosrawipour et al., 2016a, Solass et al., 2012a, Khosrawipour et al., 2016b), 
living animals (Solass et al., 2012b) and postmortem swine models 
(Khosrawipour et al., 2016c) mimicking the abdominal cavity, were used with both 
advantages and disadvantages. In the present work, the inverted bovine urinary 
bladder as a new preclinical model is introduced.  
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1.1 The Peritoneum – barrier and carrier 
The peritoneum is a serous membrane consisting of a single layer of mesothelium 
and a thin layer of connective tissue. It is situated in the abdominal cavity and 
forms the lining of the abdominal organs such as stomach, liver, spleen, part of 
the pancreas and the major parts of the small bowel and colon. In women, also 
the ovaries and fallopian tubes are situated intraperitoneally. The functions of the 
peritoneum are a leading structure for the nerves, blood vessels and lymph 
vessels of the abdominal organs and a support of stability by keeping the 
structure of the abdominal cavity in shape (Reymond and Solass, 2014). 
The lining of the inside of the abdominal cavity is called parietal peritoneum, the 
cover of the organs visceral peritoneum. It must be noted, that only the parietal 
peritoneum is innervated and thus sensitive to pain. Inflammation of the inner 
organs or adhesions within in the abdominal cavity can irritate the peritoneum 
and consecutively cause severe abdominal pain, which is felt vague and difficult 
to locate.  
The complete surface area of the peritoneum is approximately 1.5 - 2 m² 
(Albanese et al., 2009). The visceral and parietal layers form a potential space 
between each other, called the abdominal cavity. This is filled with a serous 
lubricating substance (50ml), which allows both layers to glide smoothly over 
each other. While laparoscopic interventions, this potential space is inflated with 
CO₂, forming the capnoperitoneum (Alijani et al., 2004). 
In addition to the production of the peritoneal fluid, the peritoneum has also other 
functions. Specifically, it serves as a defense barrier against intra-abdominal 
infections and cancer invasion (West et al., 2010). 
The peritoneum and its underlying lymphatic system are connected through a 
multitude of minute orifices. Thus, the free tumor cells tend to deposit on 
lymphatic spots, from where they infiltrate the beneath lymphatic system. This 
process primarily takes place on the surface of the diaphragm, the greater 
omentum, the small intestine mesentery, the epiploic appendices of the large 
intestine and the pelvic peritoneum. In comparison to that, liver, spleen, or 
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stomach are affected only in the final stadium of peritoneal disease (Losa et al., 
2014). 
1.2 Peritoneal metastasis 
The extensive infestation of the abdominal lining through malignant cells forming 
tumor implants is called peritoneal metastasis (PM). The aspect of PM can be 
very variable. Tumor nodules can vary in size, number and distribution, with or 
without infiltration into the visceral organs (Chu et al., 1989). In general, they are  
the consequence of other malignancies such as colon, gastric or ovarian cancer 
(Halkia et al., 2014). 
There are many factors, why PM is difficult to treat and the survival period still 
unsatisfactory. To begin with, the surface of the peritoneal cavity is large with an 
area of up to 2.0 m². As some parts of the abdominal cavity are very difficult to 
reach, liquid intraperitoneal chemotherapy is not able to distribute homogenously 
within the cavity, leaving tumor tissue remain untreated (Dedrick and Flessner, 
1997). Thus, the chemotherapeutic agent applied through intraperitoneal 
chemotherapy is absorbed inadequately and therefore cannot develop its entire 
cytotoxic effect. In addition to that, resistance of PM to systemic chemotherapy 
can also be explained by molecular mechanisms (Griffiths et al., 2011). 
1.3 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC)  
1.3.1 Principle 
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) is a new therapeutic 
approach to treat PM in patients with gastrointestinal and gynecological cancer. 
The basic idea of PIPAC is to improve the application form of intraperitoneal 
chemotherapy by creating a drug-containing aerosol, which is administered under 
pressure into the closed abdominal cavity. Main objective of this new technology 
is to achieve a more homogeneous distribution of chemotherapeutic agents 
within the abdominal cavity and a maximum penetration depth into peritoneal 
tissue (Reymond et al., 2000, Solass et al., 2014). 
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It must be noted that PIPAC technology combines two basic principles. On the 
one hand, there is the application form, in which a therapeutic agent is insufflated 
into the abdominal cavity as a pressurized aerosol. On the other hand, the 
environment, in which PIPAC is performed, can be steered effectively by 
modifiying physical and chemical parameters. For example, the temperature of 
the capnoperitoneum, the established pressure and the duration of application 
can be varied. The optimal combination of the form of drug administration and 
the environmental properties is the key to therapeutic success.  
PIPAC incorporates well-documented approaches of chemotherapeutical 
treatment. By using the minimally invasive laparoscopy technique, it is possible 
to repeat PIPAC application several times within a limited period (Solass et al., 
2014). Furthermore, this approach is associated with no substantial therapy-
related detoriation of quality of life (Odendahl et al., 2015). In addition, the 
pharmacokinetic advantages of intraperitoneal administration (low systemic 
toxicity and higher intratumoral concentration) and of the pressurized nebulization 
(improved penetration and distribution) complete the benefits of this treatment 
technique (Grass et al., 2017, Solass et al., 2012b, Robella et al., 2016, Solass 
et al., 2014). 
1.3.2 Technological setting 
In a first step, a capnoperitoneum is established with a constant pressure of 
12mmHg. Then, a 12-mm trocar is placed infraumbilically, through which the 
Capnopen®, applying the aerosol, is inserted. A 5-mm trocar, situated in the 
lateral hemiabdomen, provides access for the camera. After tightness of the 
abdominal cavity is confirmed by indicating no CO₂  flow, the drug containing 
aerosol is first aerosolized and the applied by the nebulizer and the injector with 
a constant with a flow rate of 30 ml/min. The maximum upstream pressure of the 
high-pressure injector is set at 200 psi (≈ 13.8 bar)(Cazauran et al., 2018). After 
an exposure time of 30 min, the capnoperitoneum and the chemotherapy aerosol 
are removed via high-efficiency particulate arrestance filter system. 
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During exposure time, the surgeon has the possibility to take biopsies of 
peritoneal lesions.  
The process of applying PIPAC technology has been determined using clinically 
established values. These include the capnoperitoneum of 12 mmHg, the 
Capnopen® position at a distance of 8 cm to the peritoneal surface of the small 
intestine and the present formulation of the drug, as an aqueous solution. The 
influence of these established parameters on the penetration depth of a 
therapeutic drug (in this case doxorubicin) in the target tissues has recently been 
investigated in an ex vivo model (Khosrawipour et al., 2016b). In this experiment, 
distance between the nozzle of the nebulizer and the sample located on the 
opposite site of the box (spray jet sample) was varied within a range of 2 to 8 cm 
and its influence on penetration depth was evaluated. The results revealed that 
the mean penetration depth was higher the closer the nebulizer was located 
towards the spray jet sample. Interestingly, in all other samples located on the 
Figure 1: Schematic PIPAC operational setting 
A normothermic capnoperitoneum is established with a pressure of 12 mmHg. Then, a 
chemotherapy solution is aerosolized with a nebulizer and injected into the tightly closed 
abdominal cavity. After 30 min of maintenance, the toxic aerosol is exhausted through the closed 
aerosol waste system (CAWS) [adapted from (Solass et al., 2014)]. 
Optimization of the spatial distribution of a therapeutic pressurized aerosol (PIPAC): an ex-vivo 
study  D.P. Schnelle 
_______________________________________________________________ 
17 
 
wall, the bottom cover and the top, penetration depth was registered to be lower 
the closer the nebulizer was brought to the spray jet sample (Khosrawipour et al., 
2016b). Concerning doxorubicin concentration, a higher concentration induces 
relevant increase of penetration depth in the spray jet sample, but only marginal 
change in the other peripheral samples. An increase of pressure did not show 
any relevant increase of penetration depth in any of the samples, including the 
spray jet one (Khosrawipour et al., 2016b).  
1.3.3 Postulated advantages 
PIPAC has a substantial pharmacological advantage compared to other 
intraperitoneal chemotherapy concepts such as HIPEC or catheter-based 
intraperitoneal chemotherapy. PIPAC can be applied repetitively and does not 
need CRS in advance. It might be more effective to achieve control of peritoneal 
residuals because the period in which tumoral tissue is exposed to  
chemotherapeutic drugs can be expanded to several months (Tempfer et al., 
2015b). Many studies have verified, that repeated application of this new method 
is tolerated very well with justifiable side effects (Nadiradze et al., 2016, 
Demtroder et al., 2016, Tempfer et al., 2015b, Solass et al., 2014) (Grass et al., 
2017).  
Another advantageous aspect of the PIPAC technology is to measure repetitively 
the outcome of antitumor treatment. During PIPAC application, the surgeon 
enters the abdominal cavity through laparoscopy. This allows him to take tissue 
samples out of specific regions of the abdominal cavity each time PIPAC is 
performed. In this way, the effectiveness of chemotherapeutic application can be 
directly judged by comparing both the PMIs, which are created in each session 
of PIPAC, and the histologic specimens removed (Solass et al., 2016). 
In tumoral tissue, increased intratumoral pressure caused by various mechanism 
(see below) leads to decreased influx of drugs into the tissue (Heldin et al., 2004). 
By establishing a capnoperitoneum with a positive pressure of 12 mmHg during 
PIPAC, this important limiting factor for drug uptake is opposed effectively 
(Reymond et al., 2000). 
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PIPAC offers a new possibility of treatment for patients in a salvage situation, in 
which usually intravenous palliative chemotherapy has only limited efficacy. In 
the last few years, PIPAC has been introduced as a new approach to treat PM in 
patients with colorectal, gastric, and ovarian cancer. In patients not eligible for 
CRS and HIPEC, this new approach delivered promising results concerning the 
regression of tumor nodule size (Tempfer et al., 2015b, Demtroder et al., 2016, 
Nadiradze et al., 2016). Yet, an important issue in stratifying the therapy in 
patients with PM is to stage the dissemination of the disease and then evaluate 
if CRS and HIPEC can be applied or not. There are cases, where CRS and 
HIPEC is not possible due to an already large dissemination as indicated by a 
high Peritoneal Cancer Index (PCI) (Sugarbaker and Jablonski, 1995). Patients 
with diffuse small bowel involvement cannot be treated with this combination 
method either (Marmor et al., 2016). In these cases, PIPAC offers a new 
possibility of “neoadjuvant” treatment. In a pilot study, Girshally et al recently 
reported the possibility of applying PIPAC for decreasing the diffuse peritoneal 
spreading to a more localized tumor involvement, so that the criteria for CRS and 
HIPEC will be met (Girshally et al., 2016). Yet, these first promising results have 
not been confirmed by randomized phase II/III trials. 
1.3.4 Current evidence – state of the art 
In the last few years, several experimental (including in vivo, ex vivo and 
postmortem experiments) and clinical studies have been published with the aim 
of investigating both the basic pharmacokinetic and pharmacodynamic principles 
of PIPAC technology and the efficacy, safety, and feasibility of PIPAC procedures 
in the clinical background.  
In 2000, Reymond et al. for the first time described the concept of a therapeutic 
capnoperitoneum, but technical limitations impeded further clinical development 
(Reymond et al., 2000). Twelve years later, Solass et al. published the first data 
about PIPAC technology. In an functioning swine model, distribution of methylene 
blue within the abdominal cavity was investigated by assessing the stained 
peritoneal surface at autopsy. Hereby, stained peritoneal surface was larger 
using the PIPAC technology compared with peritoneal lavage. Furthermore, 
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staining appeared more intense and hidden peritoneal regions were only reached 
by methylene blue through the pressured spraying (Solass et al., 2012b). 
In another preclinical model, a nontoxic therapeutic agent (Dbait, i.e. noncoding 
DNA fragments) was aerosolized under pressure into a box containing diseased 
human peritoneum. Dbait were coupled to cholesterol molecules to facilitate 
intracellular uptake and to Cyanine to be detected by fluorescence (Solass et al., 
2012b). Conventional lavage containing the same agents was applied to the 
control group. In fluorescence microscopy, penetration depth of 1mm into the 
tumor was achieved in the nebulized sample, but no fluorescence activity was 
detected after conventional lavage. In addition to that, detection of histone 
gamma-H2AX indicated activation of DNA-dependent protein kinase by Dbait and 
therefore a biological, cytotoxic effect (Solass et al., 2012a).  
As the next consecutive step, PIPAC was first applied in November 2011 in three 
end-stage patients with PM from gastric, appendiceal and ovarian origin, who had 
already undergone intravenous chemotherapy. In this small case series, the 
objective was to examine the distribution pattern, histological response, possible 
side effects and feasibility of the technology. No serious side effects ≥2 according 
to the Common Terminology Criteria for Adverse Events (CTCAE) were 
observed. Furthermore, the procedure could be carried out without any major 
obstacles and early hospital discharge was possible. On a histological basis, 
three patients had a histological remission (two of them complete, one partial) 
(Solass et al., 2014). 
During the further development of PIPAC, not only efficacy and safety were the 
issues to be investigated, but also particular attention was paid to the spatial drug 
distribution pattern. For this, PIPAC was performed in an ex-vivo model 
containing native fresh tissue samples of swine peritoneum. Aim of this study was 
to understand the drug distribution in space and penetration depth into the located 
tissue. Here, the results revealed an unequal penetration depth of doxorubicin in 
the different samples with a significantly higher depth in tissue directly exposed 
to the device jet (Khosrawipour et al., 2016a).  
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In the currently standard clinical setting of PIPAC, there are several parameters, 
including Capnopen® position, pressure, formulation of chemotherapeutic drug 
containing solution, time period of application and selection of suitable 
chemotherapeutics, which influence the drug distribution pattern and the 
penetration depth. For a better understanding of the effect of the position of the 
Capnopen®, the internal pressure and the doxorubicin dosage, Khosrawipour et 
al. designed an ex-vivo experiment model, in which these parameters were 
evaluated (Khosrawipour et al., 2016b). In another experiment, the penetration 
depth of doxorubicin after PIPAC application was examined in a postmortem 
swine model (Khosrawipour et al., 2016c). On a more physical basis, Göhler et 
al. described the technical properties of the Capnopen® and the granulometric 
characterization of the aerosol (Gohler et al., 2016). 
Based on the first data indicating a good safety of PIPAC, the technology has 
then been evaluated in patients with recurrent PM of various origins. Several 
studies reported clinical outcomes in patients with PM from colorectal, gastric, 
and ovarian cancer and PMP (Tempfer et al., 2014a, Tempfer et al., 2014b, 
Tempfer et al., 2015b, Demtroder et al., 2016, Solass et al., 2014, Giger-Pabst et 
al., 2018).  
The design of these clinical studies was diverse, consisting of prospective case 
series (Tempfer et al., 2014a, Solass et al., 2014), retrospective studies (Robella 
et al., 2016, Nadiradze et al., 2016, Demtroder et al., 2016, Girshally et al., 2016), 
a cohort study (Tempfer et al., 2015a) and case-reports (Giger-Pabst et al., 2015) 
(Tempfer et al., 2014b). 
 In the prospective single-arm phase-II study, Tempfer et al assessed the safety 
and activity of PIPAC technology in women with recurrent ovarian cancer. 62% 
of the enrolled patients responded significantly to the treatment, 76% showed 
histologic regression and PM Index improvement. Side effects were tolerable with 
CTCAE no higher than 3. Moreover, common toxic effects of chemotherapy, as 
for example nausea/vomiting, appetitive loss, constipation, diarrhea, were 
reported to improve during therapy. Overall, these results in ovarian cancer were 
promising and confirmed by various retrospective cohort investigating objective 
Optimization of the spatial distribution of a therapeutic pressurized aerosol (PIPAC): an ex-vivo 
study  D.P. Schnelle 
_______________________________________________________________ 
21 
 
tumor response and histological regression in patients with recurrent PM of 
various gastrointestinal and gynecological origins (Tempfer et al., 2015b). 
As the current standard drug concentrations in PIPAC therapy are relatively low, 
it is important to evaluate, whether the current satisfactory tolerability of the 
treating regime is because of the low systemic uptake or the low drug doses 
applied (Grass et al., 2017). Tempfer et al. showed, that no dose limiting toxicities 
were found after escalating the dose of doxorubicin and cisplatin from 1.5mg/m² 
to 2.1 mg/m² (respectively 7.5mg/m² to 10.5 mg/m²) (Tempfer et al., 2018). 
At the moment, on ClinicalTrials (clinicaltrials.gov), five further phase-II trials can 
be identified:  
 An open-label, single-arm trial investigating the feasibility, safety, tolerability, 
preliminary efficacy, costs, and pharmacokinetics of repetitive electrostatic 
pressurized intraperitoneal aerosol chemotherapy (ePIPAC-OX) as a 
palliative monotherapy for patients with isolated unresectable colorectal 
peritoneal PM (clinicaltrials.gov Identifier: NCT03246321). 
 A non-randomized, non-blinded cohort study invetigating the therapeutic 
effect of adjuvant PIPAC in resected high risk colon cancer patients 
(clinicaltrials.gov Identifier: NCT03280511). 
 An open-label, single arm trial concerning the feasibility, efficacy and safety 
of PIPAC with oxaliplatin, cisplatin and doxorubicin in patients with PM from 
colorectal, ovarian, gastric cancer or with mesothelial primary 
(clinicaltrials.gov Identifier: NCT02604784).  
 An open-label, single arm trial investigating the benefit of dose escalation of 
Oxaliplatin in PIPAC therapy for nonresectable peritoneal metastases of 
digestive cancers (clinicaltrials.gov Identifier: NCT03294252). 
 An open-label, single arm, cohort study evaluating the efficacy of PIPAC 
against PM (clinicaltrials.gov Identifier: NCT03287375). 
The present work aims at contributing to a deeper understanding of distribution 
and penetration depth of chemotherapeutic drugs, offered intraperitoneally as a 
pressurized aerosol during PIPAC therapy. 
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1.3.5 Limitations  
Despite the above mentioned achievements, there are still limitations PIPAC 
technology is struggling to overcome. Applying standards regarding injection 
pressure, exposure time, availability, chemotherapeutic dose, injection angle, 
selection of chemotherapeutic drug and tolerable toxic side effects are still under 
intensive investigation and need to be evidenced to guaranteeing the best 
outcome.  
First, the effect of pressure on the penetration depth still provides space for 
discussion. In an ex-vivo study, comparing different pressure levels and its 
impacts on penetration depth, increased pressure in the model box did not lead 
to a substantial higher penetration depth into the tissue (Khosrawipour et al., 
2016b). Other studies reported a strong positive effect of increased 
intraperitoneal pressure on the drug uptake into tumoral tissue (Heldin et al., 
2004, Minchinton and Tannock, 2006, Jacquet et al., 1996). 
Second, the positioning of the Capnopen® has been shown to have a great 
impact on the target tissue in the spray jet, but not for the other peripheral 
samples.  Yet, only a more homogenous distribution will effectively grant 
treatment conditions, no matter where exactly in the abdominal cavity the tumor 
nodules are located. To overcome this limitation, Khosrawipour et al have 
proposed various modifications for the application device. The Capnopen® could 
be placed at the most outlying position of the abdominal cavity. Furthermore, it 
could rotate during injection phase to ensure more equal distribution of the 
chemotherapeutic agent. Another idea would be to add several devices 
administering the aerosol from different directions(Khosrawipour et al., 2016b). 
1.3.6 Side effects of chemotherapy 
Systemic chemotherapy is the standard of care in patients with PM (Franko et al., 
2016).There is a range of side effects, depending on the type of 
chemotherapeutic drug applied. Especially the fast dividing cell lines such as 
blood cells and the cells lining the mouth, the stomach and the intestines are 
affected. In general, toxicities related to the chemotherapy can occur in direct 
Optimization of the spatial distribution of a therapeutic pressurized aerosol (PIPAC): an ex-vivo 
study  D.P. Schnelle 
_______________________________________________________________ 
23 
 
temporal context (acute side effects) or develop chronically, between months and 
years. 
Common acute side effects occurring after administration of chemotherapeutic 
drugs include nausea, vomiting, mucositis, diarrhea, paresthesia, cutaneous 
symptoms and alopecia (Odendahl et al., 2015). With regards of organ 
involvement, side effects typically include renal toxicity (cisplatin), neurotoxicity 
(oxaliplatin) and cardiac toxicity (doxorubicin) (Rossi et al., 2003, dos Santos et 
al., 2012, Carvalho et al., 2009). In general, systemic side effects occur less when 
chemotherapy is applied intraperitoneally (Emoto et al., 2012).  
In PIPAC technology, cisplatin and doxorubicin are commonly administered with 
a tolerable locoregional toxicity. Only 10 % of the usual systemic drug dose is 
applied into the abdominal cavity. The systemic drug concentration is limited with 
1 % of the systemic dose and 5 % of the HIPEC dose (Blanco et al., 2013). 
In a pilot study, Blanco et al investigated the impact of PIPAC technology on renal 
and hepatic toxicities. Data obtained from three patients showed that PIPAC does 
not cause significant renal or hepatic toxicity. Laboratory values of gGT showed 
a slight increase in the first few postoperative days with a decrease afterwards; 
Bilirubin, Alkaline phosphatase and Quick did not change remarkably. Also, the 
serum creatinine levels stayed stable after application. No cumulative toxicity was 
observed after repeated applications of PIPAC (Blanco et al., 2013). In another 
trial with a larger patient cohort (14 patients, 40 PIPAC procedures, combined 
with systemic chemotherapy) no significant hepatic and renal toxicity was 
induced and no major postoperative complications (CTCAE ≥3) were observed 
(Robella et al., 2016). 
In addition, different studies have shown that through establishing a positive 
intraabdominal pressure with a capnoperitoneum of 12 mmHg, both the portal 
and the renal blood flow impaired (Demyttenaere et al., 2007, Blanco et al., 2013, 
Schilling et al., 1997). An increase of the intraabdominal pressure by 5 mmHg 
leads to a significant blood flow decrease by 39% to the liver and 60% to the 
peritoneum. The longer the application time was, the less blood was transported 
through the splanchnic area (Schilling et al., 1997). These findings imply, that the 
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limited blood inflow into the abdominal organs during PIPAC application naturally 
leads to decreased outflow from the splanchnic circulation to the systemic 
compartment. This constellation favours both the bioavailability of the 
chemotherapeutic drug in the peritoneal tissue and a low systemic plasma 
concentration. As already mentioned above, the systemic drug concentration of 
doxorubicin is minimal, reaching about 1 % of the systemic dose and around 5 % 
of the HIPEC dose (Tempfer et al., 2018, Blanco et al., 2013). 
1.4 Physical parameters 
The following sections give insight into the physical parameters and central 
issues of PIPAC administration. 
1.4.1 Aerosol 
An aerosol is a heterogenous mixture of fine solid particles or liquid droplets and 
air or another gas. In nature, typical examples are fog, clouds, smoke, and soot. 
One must distinguish between monodisperse and polydisperse aerosols. 
Monodisperse aerosols contain particles of uniform size. However, most 
produced aerosols contain particles with a wide range of different particle 
diameters. In medicinal context, an aerosol is a drug containing substance, 
packaged under pressure with a gaseous propellant for release (Dictionary, Juli 
2017). As a standard of care, aerosol sprays (containing cortisone, β2-adrenergic 
receptor agonists) are used in pulmonary medicine (Cazzola et al., 2012, Rubin, 
2010). 
The basic idea of using an aerosol for intraperitoneal chemotherapy is to take 
advantage of the physical properties of a gas, which expands homogenously 
within a closed space. In theory, the entire surface of the peritoneum can be 
reached by the drug-containing aerosol, which is one of the main advantages 
compared to conventional peritoneal lavage, where not all parts of the abdominal 
cavity are covered sufficiently. However, although an aerosol fulfils certain criteria 
to be regarded “gas-like”, one must keep in mind, that the generated aerosol also 
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contains droplets in the micrometer-size range, which clearly differ from the 
behavior of a perfect gas. 
Scientific research on the droplet size distribution of the generated aerosol during 
PIPAC has presented a wide range of generated droplet sizes. Khosrawipour et 
al described that the Capnopen® sprays with a droplet diameter ranging from 3 
– 15 µm (Khosrawipour et al., 2016a). In ex-vivo granulometric analysis by laser 
diffraction spectrometry, Göhler et al found out, that more than 92.5 number% of 
the released droplets have a diameter below 3 µm. Interestingly, considering the 
volume-weighted distribution, 97,5 vol% of the liquid is part of droplets with a 
diameter ≥3µm. In other words, most of the volume of the released droplets turns 
up in a few larger droplets, whereas the majority of the droplets contains just a 
minimal fraction of the entire volume. Thus, most of the liquid volume is deposited 
either by inertial impaction or by gravitational settling. Only a small fraction of the 
liquid is carried by droplets in the sub-micrometer range diffuse in space like an 
ideal gas. Furthermore, two major peaks in the distribution curve of the generated 
droplets exist, beside one mode <3 µm, a second mode showed values between 
10 and 15 µm (Gohler et al., 2017). 
In the scientific community, there is still discussion about the appropriate droplet 
size diameter. The liquid particles of the aerosol behave the more “gas-like”, the 
smaller the diameter is. The equation of Stokes shows, that halving the diameter 
leads to a four times diminished sedimentation velocity (Britannica, April 11, 
2016). Rubin et al announced, that if an aerosol is supposed to behave “gas-like”, 
the diameter should not exceed 1µm (Rubin, 2010). However, one must keep in 
mind, that creating liquid droplets with a diameter <1 µm is not only very difficult 
to achieve, it might also not even be necessary, since the therapeutic aerosol is 
even supposed to deposit after a certain time. Therefore, it is only important to 
approach to the characteristics of an ideal gas to guarantee sufficient 
homogenous distribution within the abdominal cavity. 
An ideal gas will expand homogenously within a closed space. Yet, an aerosol 
does not behave “gas-like”, i.e. distribute homogenously within a closed space 
such as the abdominal cavity, but the liquid droplets of the aerosol will eventually 
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deposit due to different mechanisms. As mentioned above, through inertial 
impaction, larger particles deposit on the ground. Furthermore, gravitational 
forces lead to a sedimentation of smaller particles. This process is time 
depending, the smaller the particles, the slower the deposition.  
In general, so far, there is just little knowledge about the mechanisms of aerosol 
therapy into the abdominal cavity. Much more information about the basic 
principles of aerosol therapy in pulmonary medicine is available. Aerosol therapy 
in pulmonary medicine is very demanding due to some major obstacles such as 
a needed patient compliance, a small anatomic diameter of the bronchial tubes, 
a complex geometry of the space of application (bronchial tree) and the 
impossible chemical and physical control.  
Compared to that, abdominal aerosol application stands out for its low fragility of 
the application system, the absence of needed patient compliance, the large 
anatomic diameter, and the simple geometry of the abdominal cavity. Above all, 
the possibility of steering the environmental setting, as mentioned above, is 
regarded as a very important tool in effective tumoral treatment.  
The creation process of an aerosol is based on two pathways: the technical 
devices and the drug-containing solution. In the available schematic overview, 
both pathways are considered equally important. The drug needs to have the 
required concentration in the solution. The angioinjector provides the upstream 
pressure, which is needed for the nebulizer to atomize the supplied solution and 
to spray it into the abdominal cavity. Only if all steps are coordinated accurately, 
the target effect on the tissue will fulfil the necessary requirements. 
1.4.2 Distribution pattern 
A homogenous distribution of chemotherapeutic agents within the abdominal 
cavity contributes considerably to an improved effectiveness of intraperitoneal 
tumor treatment. The abdominal cavity is subdivided into different regions (Solass 
et al., Pleura and Peritoneum 2017). As some parts of the abdominal cavity are 
very difficult to reach, intraperitoneal chemotherapy is not able to distribute 
homogenously within the cavity, leaving poorly or untreated tumor tissue behind 
Optimization of the spatial distribution of a therapeutic pressurized aerosol (PIPAC): an ex-vivo 
study  D.P. Schnelle 
_______________________________________________________________ 
27 
 
(Khosrawipour et al., 2016a). Another aspect, that should be taken into concern 
is the fact, that administering a drug containing fluid into the abdominal cavity is 
also subject to the principles of gravitation forces. Thus, after administration and 
depending on time, the liquid is deposited in the deepest part of the abdominal 
cavity. Regions, situated under the abdominal wall, might not be reached 
adequately. Even more, after surgical intervention, patients often develop 
adhesions, which mark major obstacles in optimal drug distribution, because 
further PIPAC procedures might become impossible to perform (Nadiradze et al., 
2016, Girshally et al., 2016). 
1.4.3 Drug concentration 
The drug concentration of the aerosolized solution in the abdominal cavity is very 
important for several reasons.  As small peritoneal tumor nodules (<1mm) are 
Figure 2: Quality by Design concept applied to the process of PIPAC procedure 
Schematic overview of optimizing the therapeutic aerosol. Starting from the target effect onto the 
tissue, the aerosol is optimized by determined upstream parameters (device, solution) as well as 
by steering the intraabdominal environment (temperature, pressure, pH-value, charge). 
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either poorly or not vascularized, intravenously administered chemotherapy does 
not reach its target, resulting in inefficient cytotoxic effects. For these nodules, a 
higher drug concentration is potentially advantageous. On the other hand, the 
currently used cytotoxic drugs are characterized through a steep dose-effect 
relationship, where a doubling of the dose will lead to multiplied toxic effects. 
(Ceelen and Flessner, 2010). 
As currently standard of care, the concentration of doxorubicin and cisplatin in 
the atomized solution is determined with values of 10.5 mg/m² body surface 
(cisplatin) and 2.1 mg/m² (doxorubicin). These concentrations are supposed to 
ensure sufficient effectiveness in combating tumor cells combined with 
acceptable locoregional side effects (Blanco et al., 2013).  
Recently, it was proposed that higher drug concentrations of 
Cisplatin/Doxorubicin were still well tolerated without major systemic toxicity. The 
maximum tolerable dose was not reached (Tempfer et al., 2018). 
1.4.4 Hydrostatic pressure within the abdominal cavity 
One must distinguish between the applied upstream pressure of the angioinjector 
and the elevated pressure while installing a capnoperitoneum. The drug is 
delivered via the angioinjector with an upstream of approximately 20 bars.  
The elevated pressure in the abdominal cavity during PIPAC procedure has 
various consequences, such as increased intratumoral drug concentration 
(Jacquet et al., 1996), effective counteraction of the hydraulic capillary pressure 
(Minchinton and Tannock, 2006, Esquis et al., 2006) and a decreased drug 
outflow to the body compartment (Blanco et al., 2013, Schilling et al., 1997). 
Theoretically, the higher the intraabdominal pressure is set, the deeper the 
chemotherapeutic agents could possibly penetrate. The elevation of the 
intraabdominal pressure during laparoscopy is limited by hemodynamic and 
respiratory issues (Schilling et al., 1997). Therefore, in clinical practice, the 
current limit of intraabdominal pressure during HIPEC is 10 – 15 mmHg (Garofalo 
et al., 2006); for PIPAC applications, 12 mmHg is the standard of treatment 
(Nowacki et al., 2018). 
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1.4.5 Depth of drug tissue penetration 
The penetration depth is an important marker to analyze the efficacy of 
chemotherapeutic therapy. The deeper a cytotoxic agent can infiltrate into 
tumoral tissue, the more tumor cells are killed.  
Theoretically, a high penetration depth can be achieved by applying a positive 
pressure in the abdominal cavity (pneumoperitoneum). Thus, the therapeutic 
drug containing aerosol will penetrate deeper inevitably due to physical laws. 
Additionally, the homogenous drug distribution pattern also plays a role, which 
should not be underestimated. As described later in detail in the chapter 
“discussion”, effective penetration into peritoneal tissue only happens in regions 
of the cavity, where the aerosol has been propagated and stayed during the 
exposure period of PIPAC application.  
In conventional lavage of the abdominal cavity, reported penetration depth results 
are variable ranging from a few cell layers (for Doxorubicin and Mitoxantrone), 2 
mm (for Mitomycin C and Oxaliplatin)(Ceelen and Flessner, 2010) up to 3-5mm 
(for cisplatin)(van de Vaart et al., 1998) with a mean tissue concentration of 0.03 
µmol/g (Jacquet et al., 1996). Compared to that, PIPAC shows a 
chemotherapeutic penetration depth both into tumoral and peritoneal tissue 
reported at 300 – 600 µm and parallel to that a significantly higher tissue 
concentration (up to 4.1 µmol/g) (Solass et al., 2014). 
1.5 Scientific problem 
One of the central issues in PIPAC research is the achievement of homogeneity 
of drug distribution within the abdominal cavity. In the scientific community, there 
is consent about the fact, that a homogenous drug distribution is a precondition 
for approaching the long-term goal of treating PM with a curative approach. 
In the past, many efforts have been made to describe and improve the distribution 
pattern of an aerosol. Different models including in vivo, ex vivo and postmortem 
swine experiments have dealt with the relation between the injected aerosol, the 
distribution pattern within the abdominal cavity and the penetration depth into the 
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serosal tissue.  Yet, homogeneity in drug distribution could not yet be achieved 
in a satisfactory manner. All presented models suffer from different limitations. In 
order to move scientific research of the PIPAC technology forward, is has become 
essential to develop new preclinical models.  
In this context, a new ex vivo experimental model, the inverted bovine urinary 
bladder, is introduced as one key element of this dissertation. Detailed 
information about the experimental set up and the advantages of this model will 
be given in the following chapters.   
In all established models, measurements only recorded the result of application, 
as defined by serosal staining, tissue concentration or penetration depth. This is 
a significant restriction, since aerosol distribution is not static, but time-
depending. Thus, in the present work, the Thermographic Imaging, an 
established method in other contexts, is introduced as another new dynamic 
experimental model, analyzing the injection behavior and the consecutive spatial 
distribution of the aerosol over time in a closed space. 
This dissertation puts its focus on the description and improvement of the aerosol 
distribution pattern. In doing so, in the following chapters, the physical properties 
of two aerosols, created by two different nebulizers, the Capnopen® and a 
prototype device (in the following called Protoype4), will be analyzed in various 
series of experiments. The objective of these experiments is to gain a deeper 
understanding of the drug distribution pattern of aerosols with improved 
characteristics and their effects on the penetration depth and drug concentration 
in the serosal tissue. 
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2 Methods 
2.1 Ethical and regulatory framework 
This study involved no human patients and no human tissue, therefore no 
approval by the Ethics committee of the University of Tübingen was needed. 
Fresh biological tissue was obtained from the slaughterhouse from animals 
sacrified for the alimentary chain. No living animal was used or sacrified for the 
purpose of this study, therefore no application to the local Animal welfare 
committee was required. 
2.2 Study design 
This is an experimental study using in-vitro and ex-vivo models for comparing the 
performance of two medical devices: the CE-certified Capnopen® (Capnomed 
GmbH, Villingendorf, Germany) vs. a second-generation instrument (“Prototype 
4”), provided by the same company. This research was performed under the 
umbrella of a contract research agreement between Capnomed GmbH and 
University of Tübingen. The study was fully funded by Capnomed GmbH.  
Results were documented according to the good scientific practice standards of 
the German Research Foundation (DFG) and comply with the “Empfehlungen zur 
Führung eines Forschungs-Protokollbuches” of the Faculty of Medicine, 
University of Tübingen (Version 12/2017). Experimental records were uploaded 
on the LabGuru platform of the research group (AG PIPAC).  
For being able to evaluate the medical devices, it was first necessary to develop 
adequate models, since such models were not available. Since it would appear 
unethical to perform a large number of experiments in animals, we first developed 
two preclinical models: a Thermographic Imaging in-vitro model and an ex-vivo 
model using biological tissue: the inverted bovine urinary bladder model.  
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2.3 In-vitro models  
In a first step, we measured the granulometric characteristics of the aerosol 
depending on the medical device design. For this purpose, we used an 
established, FDA-approved method for analyzing medical aerosols.  
In a second step, we evaluated homogeneity of aerosol distribution depending on 
the device. For this purpose, we proposed, developed and implemented a new 
model to visualize spray propagation by Thermographic Imaging.   
2.3.1 Granulometric analysis  
Droplet size distribution analyses were performed by laser diffraction with the 
SprayTec® droplet analyzer (Malvern Instruments, Worcestershire, UK).  
The helium-neon laser, located in the transmitter, emits a 10-mm light beam 
(wavelength: 632,8mm). Through the aerosol droplets, the laser light is scattered 
and recorded via the silicon-diodes detector array (detection rate: 1 Hz) in the 
receiver. The distraction of the laser light is transformed into the droplet size 
distribution by means of defined mathematic algorithms (Fraunhofer theory). The 
Figure 3: Experimental setup of the SprayTec® droplet analyzer 
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SprayTec® droplet analyzer can detect droplet diameter within a range of 0.1 – 
2000 µm. Measurements were taken for the Capnopen® and the Prototype4.  
The nebulizer was positioned in a perpendicular position 5 cm above the center 
of the open laser beam. Flowrate was 1 ml/min, 120 ml aqua was aerosolized 
and recording time was 2 min. 
2.3.2 Thermographic Imaging 
The idea of our newly developed Thermographic Imaging model was to create a 
closed gaseous environment with dimensions comparable to a human abdomen, 
and to generate a therapeutic aerosol within the closed volume with a warming 
screening placed beyond the aerosol. The hypothesis was the colder aerosol 
would “hide” the warm screen, allowing therefore to determine aerosol distribution 
in real time by thermographic recording. The experimental setup for 
Thermographic Imaging consists of a radiated surface, which is heated up to 100 
°C. In front of the surface, a cupola box with a plain ground and an arc-type roof 
is built. The ground and the upper wall consist of hard plastic plates. The 
measures of the experimental box are: height 14 cm, width 35 cm and depth 22 
cm. The front of the box is sealed by commercially available plastic wrap. 
In the center of the roof, a hole with a diameter of 15 mm is drilled, through which 
the Capnopen® is inserted in a perpendicular position, hereby the tip of the 
noddle goes 5 mm into the box.  
Thermography is an imaging method for displaying the surface temperature of 
objects. The intensity of the infrared radiation is interpreted as a measure of its 
temperature. A thermal imaging camera converts the infrared radiation, which is 
invisible to the human eye, into electrical signals, which are converted into a 
colored image. 
The thermographic camera (Seek Thermal®) is positioned 40 cm in front of the 
box and connected to a commercially available smartphone where the images 
are captured. Thus, the lens of the camera is situated at about 1 cm above an 
imaginational horizontal line, which passes the bottom of the box in the center.  
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Prior to the aerosol injection, the camera captures the uniform temperature 
distribution of 100 °C. After the aerosol injection into the box chamber, the 
temperature distribution changes, since the aerosol reduces the infrared 
radiation. The camera takes one picture every second, thus the dynamics of the 
spray propagation can be observed.  
In the experiments, both the Capnopen® and the Prototype4 were used under 
identical circumstances.  
Table 1: Injection parameters for Thermographic Imaging 
Aerosol Duration Flow rate Temperature of radiator 
aqua 30 secs 0.5 ml/sec 100 °C 
 
 
Results were obtained by visual examination and analysis of the thermographic 
images. 
 
 
Figure 4: Experimental setup of Thermographic Imaging experiments 
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2.4 Ex-vivo models 
The in-vitro models described above do not allow indeed to draw any conclusion 
on the effect of the therapeutic aerosol on the target tissue. Only through further 
development of the physiochemical properties of a therapeutic aerosol, drug 
delivery into the target cells can be optimized. For example, Khosrawipour et al. 
has demonstrated recently that the homogeneity of the therapeutic aerosol 
applied during PIPAC is not perfect. However, the experimental model used by 
these authors (tissue fragments placed into a plastic container box) was 
suboptimal because the plastic surfaces are not absorbing any substances so 
that the aerosols droplets are falling down rapidly to the floor of the container, 
due to gravity. For such a purpose, it was necessary to develop an additional, 
new model including serosal tissue. The model should be easy to use, 
reproducible and cost-effective. It should have a volume similar to the human 
abdominal cavity, and an oval shape. The inner surface should be lined with 
serosa. The model should allow pharmacological and biological analysis, 
including histology. No living animals should be used (Schnelle et al., 2017). 
2.4.1 Inverted bovine urinary bladder  
The volume of the bovine urinary bladder (2-3 l) comperes well with the volume 
of the human abdominal cavity (3-5 l). By inverting the urinary bladder, the serosal 
surface, which normally marks the outside of the organ, becomes the inner 
surface. This setting allows adequate evaluation of both drug distribution and the 
drug penetration depth into the serosal tissue. Importantly, the serosal surface is 
homogeneous, which would not be the case in an animal model where anatomical 
and physiological characteristics of the peritoneum differ between various 
locations. For example, small bowel serosa – which permits bacterial 
translocation – might be much more permeable to macromolecules than the 
gastric serosa. Thus, evaluation of the influence of technical factors on 
homogeneity of aerosol distribution in vivo might be biased by organ-specific 
factors (Schnelle et al 2017). Purpose of our first experiments was to investigate 
the feasibility of the model as well as its functionality.  
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2.4.2 Medical devices 
The experimental equipment included following components: 
- a high pressure angioinjector (Accutron HP, Medtron, Saarbrücken, 
Germany),  
- a nebulizer (Capnopen® or Prototype4, Capnomed, Villingendorf, 
Germany) 
- a CO2-insufflator (Aesculap® AG, Tuttlingen, Germany) 
- a 12 mm trocar (Kii®, Applied Medical, Düsseldorf, Germany) 
- the  inverted bovine urinary bladder 
- various connecting lines. 
Technical procedure 
All organs were obtained cooled directly from the slaughterhouse. Then, each 
bovine urinary bladder was adequately dissected and rinsed with a physiological 
solution. The bladder was incised at the neck with a 4-cm cut and then inverted. 
Afterwards, a 12-mm trocar was inserted through the neck and adequately fixed 
by closing the organ with a purse-string suture. After installing a constant 
capnoperitoneum of 12 mmHg in the inverted bovine urinary bladder, various 
solutions (Methylene blue, ICG, DAPI and Cisplatin) were aerosolized into the 
inverted bladder with a flow rate of 0.5 ml/sec. After the exposure phase (15/30 
min), the respective aerosol was evacuated over a closed system into HEPA 
filters and the bladder was disconnected from the apparatus. Then, the bladder 
was opened via a vertical cut from the neck to the bottom. Later experimental 
steps were depending on the kind of experiment (see below).   
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Comparison of two nebulizers 
The functional principle of the nebulizer is to generate an aerosol out of a liquid 
substance, which is injected under pressure into the experimental model. In the 
experiments, two different devices were tested. The Capnopen®, which is 
currently used in the operative setting of PIPAC procedures and a prototype 
(Prototype4).  
Figure 5: Experimental setup of inverted 
bovine urinary bladder experiments  
 
Figure 6: Medical devices: Capnopen® and Prototype4 
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High pressure injector 
The Accutron HP-D (Medtron®AG, Saarbrücken, Germany), a commercial high-
compression injector, was used to compress the solution with an upstream 
pressure of 40 bar. It was connected to the nebulizer via a high compression 
infusion line. 
As current operational standard of PIPAC, the injection flow rate in our 
experiments was 0,5 ml/sec. Depending on the amount of the drug-containing 
solution, the injection time varied. 
CO2 – Insufflator  
The CO2-Insufflator (Aesculap® AG, Tuttlingen, Germany) receives the CO₂ from 
a connected CO2 bottle. In the beginning of each experiment, the CO2-Insufflator 
was tightly connected via a connecting tube to the trocar, which was positioned 
in the neck of the bladder. Then, a constant positive pressure of 12 mmHg was 
established within the inverted bovine urinary bladder.  
Aerosol 
In all experiments, an aerosol was generated through the nebulizer 
(Capnopen®/Prototype4). Differences in the aerosols came from various solution 
formulations.  
Table 2: Solution formulations of inverted bovine urinary bladder experiments 
Experiment Solute Solvent Ratio Volume 
Duration 
of 
injection 
1 
Methylene 
blue 
0.9% NaCl 0.0003% 30 ml 60 secs 
2 
DAPI 
0.9% NaCl 
1 µg/ml 
100 ml 
200 secs 
ICG 10 µg/ml 200 secs 
3 Cisplatin 0.9% NaCl 
7.5 mg/m2 
body surface 
150 ml 300 secs 
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Sample Removal 
After exposure phase, the bladder was taken off from the apparatus, opened via 
a vertical cut and positioned and presented for sample removal. Standardized 8 
mm punch biopsies were taken in the experiments with DAPI and Cisplatin. 
In the distribution experiment with DAPI, six samples were removed from 
predefined areas (in each case two from the upper, middle and bottom part). 
In the distribution experiment with Cisplatin, nine samples were removed from 
predefined areas (in each case three from the upper, middle and bottom part). 
Documentation of the tissue samples included date, number of bladder, area of 
sample removal and applied nebulizer (Capnopen® or Prototype4). After 
removal, samples were immediately frozen at -80°C for histological preparation. 
2.4.3 Distribution experiments with Methylene Blue (visual 
examination) 
For photodocumentation, opened bladders were positioned with the neck of the 
bladder upside. In total, three experiments were performed with Capnopen®, one 
with Prototype4. Homogeneity of the distribution pattern was investigated 
qualitatively by visual examination.  
Figure 7: Interior view of a sliced 
inverted bovine urinary bladder after 
sample removal 
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2.4.4 Distribution experiments with ICG (macroscopy) and DAPI 
(microscopy) 
A combined solution consisting of Indocyanine green (ICG) and 4',6-diamidino-2-
phenylindole (DAPI) was created according to the parameters of table 3. 
With each device (Capnopen® and Prototype4), four series of experiments were 
performed. 
ICG as a dye is used frequently for medical diagnostic purposes such as 
visualizing liver metastases and retinal blood circulation (Handgraaf et al., 2017, 
Guerrero et al., 2017). The absorption maximum light wavelength is about 750 to 
800 nm (Alander et al., 2012). The emitted fluorescence spectrum of ICG is very 
wide, varying between 750 nm and 950nm (Sabapathy V, 2015). 
DAPI is a fluorescence dye, which is commonly used in fluorescence microscopy 
for marking DNA. The absorption maximum light wavelength is 358 nm, the 
emission maximum 461 nm. During fluorescence microscopy, DAPI is excited 
through ultraviolet light and detected using a cyan filter (Kapuscinski, 1995).  
Formulation of the solutes-containing solution was as follows: 
Table 3: Aerosol formulation and application parameters of ICG/DAPI experiments 
Solute Solvent Volume Ratio 
Injection 
Rate 
Duration of 
Injection 
DAPI 
0.9% NaCl 100 ml 
1 µg/ml 
0.5 ml/sec 200 secs 
ICG 10 µg/ml 
 
After the exposure time of 30 min, the inverted bovine urinary bladder was 
opened and positioned on a cork plate for photodocumentation of ICG. 
Afterwards, tissue samples were taken to analyze penetration depth of DAPI. 
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Photodocumentation of ICG (macroscopy) 
For photodocumentation, a completely darkened room was used. The opened 
bladder was positioned under the IC-View Camera (Pulsion Medical Systems AG, 
D-München). Excitated ICG (wavelength 780 nm) in the bladder wall was 
detected and photo-documented with the IC-View Camera. Of each bladder, one 
image was taken. Homogeneity of the ICG distribution pattern was investigated 
qualitatively by visual examination.  
The digital video camera (Sony®, Digital 8 Video Camera Recorder DCR-TRV820E) is connected 
with a fluorescence emission device (Pulsion Medical Systems AG, D-München, wavelength 780 
nm), which creates the excitation of ICG in the bladder wall 
Fluorescence Analysis of DAPI (microscopy) 
A fluorescence microscope (DM-RBE 55453®, Leica Systems, Leipzig, 
Germany) was used for DAPI penetration depth measurements. Excitation 
wavelength of DAPI is 358 nm. A filter only lets pass the DAPI fluorescence light 
(emission maximum of 461 nm). The microscope was coupled to the image-
editing program LeicaQWin (Leica Microsystems Imaging Solutions Ltd, 
Cambridge, UK), with which penetration depth measurements in the serosal 
tissue were performed.  
From each bladder, six tissue samples were taken, out of which three histological 
cuts each were created. The technically best prepared histological cut was 
selected. Out of it, three representative sections of the serosal surface were 
Figure 8: IC-View Camera 
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evaluated with three penetration depth measurements each (experiment in 
triplicate). In total, 54 measurements for each bladder were documented.   
Evaluation of tissue penetration depth was performed by an independent 
pathologist, who was blinded to the type of device used and to the position of the 
sample in the bladder.  
Figure 10: Schematic selection of three representative sections in a tissue sample 
Figure 10: Exemplary image of penetration depth measurements with 
fluorescence microscopy 
The white dotted lines indicate the three performed penetration depth measurements. See the 
serosal surface in the upright corner and the DAPI stained nuclei (blue). 10x Enlargement. 
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2.4.5 Distribution experiments with Cisplatin (tissue concentration)  
Chemotherapy experiments were conducted in order to assess the drug 
concentration in the tissue samples in predefines areas within the bladder. 
Therefore, Cisplatin was disposed with the same setup. Just Capnopen® was 
tested. Three series of experiments were performed. 
Formulation of the drug containing solution was as follows: 
Table 4: Aerosol formulation and application parameters of Cisplatin experiments 
Drug Solvent Volume Ratio Injection 
rate 
Duration of 
Injection 
Cisplatin 0.9% NaCl 150 ml 7.5 mg/m2 
body surface 
0.5 
ml/sec 
300 secs 
 
The Cisplatin-containing solution was injected for 300 secs, with an injection rate 
of 0.5 ml/sec. Exposure time was 30 min. 
Out of each bladder, nine tissue samples were taken, frozen at -80°C for 
subsequent histological preparation and analysis. 
Histological preparation and concentration analysis 
Frozen tissuee samples were lyophilized (KF-2-110; H. Saur Laborbedarf, 
Reutlingen, Germany) in the a vacuum concentrator and weighted. The pellet 
was cut into 3 - 4 little pieces, followed by resuspension in 1 ml Ampuwa water. 
Samples were homogenized with a miccra-D9 homogenizer (ART-moderne 
Labortechnik e.V) for 1 min and then sonicated in a sonicater (Electrosonic type 
07 or ELMA S30/H) for 20 min at room temperature. Afterwards, samples were 
shaken in an overhead rotator overnight at room temperature (Roto-Mix,Typ 
ROTO, neoLab, Germany). Samples are filled up with 1,0 ml Ampuwa (destilled 
water) to give a final volume of 2,0 ml followed by vortexing, centrifugation and 
aservation at -80°C until shipping. 
Finally, samples were shipped on dry ice to the laboratory “Überörtliche 
Berufausübungsgemeinschaft, Medizinisches Versorgungszentrum, Dr. 
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Eberhard & Partner” in Dortmund, where concentration measurements of 
cisplatin with atomic absorbance spectroscopy (AAS) were conducted.   
2.5 Occupational health safety aspects 
For research purpose, toxic aerosols were generated and manipulated during this 
study. The experiments were performed within a class-2 safety hood certified for 
application of cytostatic drugs (Maxisafe 2000, ThermoFisher Scientific, Dreieich, 
Germany).  All related procedures have been audited by the safety officer of 
University Hospital Tübingen and by the competent health insurance (Unfallkasse 
Baden-Württemberg) in Q4/2016. Environmental air measurements were 
performed according to a standard protocol (NIOSH 7300) by an independent 
company (DEKRA industrials, Stuttgart, Germany). No traces of platin were 
detected with a detection limit of 0.3 ng/m3 (Schnelle et al., 2017). 
2.6 Statistics 
Since this is exploratory research, no size sample was determined a priori. All 
experiments were performed in triplicate. Blinding was applied when possible, in 
particular for analysis of depth of tissue penetration. Descriptive analyses of the 
data included mean ± CI 95%, or median and percentiles. The data were 
graphically presented as box plots. Comparative statistics included non-
parametric tests for comparison of means. The statistical program SPSS Version 
22.0. (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Armonk, NY: 
IBM Corp.). Probability values were defined as follows:   were performed and the 
accompanying diagrams created. *p < 0,05; **p < 0,01; ***p < 0.001; and ‡p > 
0.05.  
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3 Results 
3.1 Granulometric analysis  
In this chapter, the results of the droplet size distribution analysis by Laser 
Diffraction are presented.  
The diagram in figure 11 shows the particle diameter distribution of Capnopen® 
(black) and Prototype4 (red) in a logarithmic scale. The y-axis indicates the 
volume frequency in percent. The values of droplet diameter distribution are 
volume-weighted. The curve of Prototype4 ascends steeper, has its peak with 
over 30 % volume frequency at the particle diameter of 34 µm (compared to 24% 
using Capnopen®), and again falls down faster compared to the curve of 
Capnopen®.  
Table 5: Comparison of different diameter values (Dv(10), Dv(50), Dv(90)) 
 Dv(10) Dv(50) Dv(90) 
Capnopen® 24.82 µm 33.81 µm 45.72 µm 
Prototype4 26.82 µm 34.24 µm 43.64 µm 
 
Values are indicated in micrometers 
Capnopen®  
Prototype4 
Frequency 7 Feb 2017 - 17:02:55
 prototyp4 25 01 2017.smea\Overlays\3 x capnopen types.pso
average *pso of diff rent capnopen types
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Date-Time File Sample Dx(10) Dx(50) Dx(90)
[V] 25 Jan 201... Wasser ... Wasser 24.82 33.81 45.72
[V] 25 Jan 201... Wasser ... Wasser 26.82 34.24 43.64
[V]=Volume [N]=Number
Figure 11: Particle diameter distribution of Capnopen® and Prototype4 
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Table 5 compares three different diameter values of both Capnopen®. The value 
Dv(50) indicates the median particle size. 50% of the droplets are below this 
value. Other important parameters are Dv(10) and Dv(90), which determine the 
range of the majority of the droplet sizes. The diameter of 80% of the droplets is 
in between these two values. The smaller the difference between Dv(90) and 
Dv(10), the more droplet size homogeneity within the aerosol exists. 
The Dv(50) of the Prototype4 is slightly higher than of  the Capnopen®. The 
Prototype4 has a lower Dv(90) and a higher Dv(10) than the Capnopen®. That 
indicates that the Prototype4 has a more uniform spray pattern with a smaller 
range of droplet size distribution compared to the Capnopen®. 
3.2 Thermographic Imaging 
3.2.1 Results of Thermographic Imaging 
The basic idea of Thermographic Imaging is to make infrared radiation, emitted 
by all bodies with a temperature level above absolute zero, visible. The amount 
of radiation, emitted by an object, increases with rising temperature. 
Thermographic cameras operate in the long-infrared range of the 
electromagnetic spectrum (approximately 9 – 14 µm). The received 
electromagnetic waves are transformed into an image with different temperature 
levels.  
Thermographic Imaging is a valid possibility to describe the spatial distribution of 
an aerosol injected into a model box over time. Here, this technique makes use 
of the fact that the appearance of an aerosol leads to decreased heat 
transmission. The more droplets of the aerosol are injected in a certain space, 
the less heat of the radiator, which is located behind the model box, can be 
transmitted, leading to a decreased temperature. This direct connection between 
number of droplets in space and decreased heat transmission is interpreted in 
the experiments. Two different nebulizer (Capnopen® and Prototype4) were used 
in the experiments. 
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Temperature levels are defined as follows: 
Table 6: Temperature levels of Thermographic Imaging 
Red area Yellow area Green area  Blue area 
77 – 84 °C 66 – 72 °C 53 – 61 °C < 49 °C 
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3.2.2 Description of the thermographic images 
Capnopen® - Images left column 
The starting image marks the beginning of injection. After 1 sec, a dark spot has 
appeared on the ground of the model box. After 3 secs, first signs of spatial 
cooling are visible in the center of the model box. A symmetrical tent-like 
Figure 12: Thermographic Imaging during injection period into model box  
Emitted infra-red radiation from a radiator, placed behind the box, is received by the Seek 
Thermal® camera and converted into thermograms. A series of 30 subsequent image pairs is 
shown, which were captured every second. The left images display the temperature pattern for 
Capnopen®, the right images for Prototype4. 
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darkening, starting mainly on the ground at first and then raising and widening 
the more aerosol is injected. Additionally, the ground area changes color from at 
the beginning yellow to green to blue, the more time passes. After 7 seconds, a 
respectable amount of aerosol droplets covers the entire ground.  
Another phenomenon can be observed from the image after 11 seconds. On the 
sides of the model box, cooling proceeds faster the in the space between the 
sides and the center. This can be explained by the flow behavior of the aerosol, 
which is injected into the center, then spreads out to the sides and finally soars 
up again.  
After 18 seconds, the red areas have finally disappeared, having changed into 
yellow and green sections.  The “w”-shaped line, marking the upper end of the 
concentrated aerosol distribution, gradually moves upwards, until after 29 
seconds, just two small dark green spots beside the central injection spot are left.  
Prototype4 - Images right column 
After starting the aerosol injection, images of both Capnopen® are comparable 
until 4 secs. Afterwards, in the right images, the central cupola grows faster with 
a larger diameter. The biggest contrast between the images of both Capnopen® 
can be observed after 10 secs. While with the Capnopen® the upper area is still 
red except for the already cooled down ground and the central aerosol flow path, 
with Capnopen® 2, the red parts in the upper center have already disappeared 
and the blue sections reach the center of the model box.  
The central conical elevation of the cooled area has a larger diameter. This 
characteristic of the Prototype4 can be best observed after 9 secs.   
Within six seconds (between image after 4 secs and after 10 secs), the entire 
volume of the model box is filled with aerosol droplets. From this point, further 
cooling of the side upper areas proceeds steadily and homogenously, until after 
29 secs, a cooling of all areas in the model box has occurred.  
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3.2.3 Comparison of properties of Capnopen® and Prototype4 
The injection angle of Capnopen® is α= 40°, while Prototype4 offers an angle of 
ß=55°. 
 
In addition, the distribution velocity of both deviced differs significantly. 
Table 7: Comparable aerosol distribution snapshots 
 
Table no. 7 shows comparable snapshots of the respective intermediate 
distribution results. The spreading degree of the aerosol of Prototype4 after 4 
secs corresponds to the spreading degree of the aerosol of Capnopen® after 5 
secs. The aerosol distribution velocity of Prototype4 is higher. Especially 
noticeably is the almost doubled time between the image of Prototype4 after 10 
secs and the image of Capnopen® after 19 secs.  
 
 
 
 
 
Capnopen® Prototype4 
5 secs 4 secs 
10 secs 7 secs 
19 secs 10 secs 
29 secs 25 secs 
Figure 13: Injection angles of Capnopen® (left) and Prototype4 (right) 
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3.3 Inverted bovine urinary bladder experiments 
In this chapter, the results of the three inverted bovine urinary bladder 
experiments are presented. 
3.3.1 Distribution experiments with Methylene Blue (visual 
examination) 
Staining of the entire serosal surface except the upper part of the bladder neck, 
which was unreachable for the aerosol due to the tight pursuing suture, was 
revealed both in the approaches with Capnopen® and Prototype4. Although the 
upper half of the bladder was dyed properly, most intense staining was observed 
in the lower parts.  
No substantial difference in the homogeneity of surface staining between the 
Capnopen® and the Prototype4 was observed. 
3.3.2 Distribution experiments with ICG (macroscopy) 
The images 1 – 4 document the four urinary bladders being sprayed with 
Capnopen®. Prototype4 was used in the bladders 5 – 8.  
 
Figure 14: Overview of the stained bovine urinary bladders after opening 
Bladders #1 - #3 were treated with Capnopen®, bladder #4 with Prototype4. Staining of all 
bladders was performed with Methylene Blue 
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Description of Fluorescence Imaging with Capnopen® 
In the images 1 – 4, the bladders sprayed with Capnopen® are shown. The upper part 
indicates the neck of the bladder. In all four bladders, ICG fluorescence emission is 
apparent.  
 
Figure 15: Photo documentation of ICG-sprinkled bladders with the Capnopen® 
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Table 8: Characteristics of ICG aerosolized bladders (Capnopen®) 
 Characteristics 
Bladder no° 1 
Image shows a homogeneous distribution of ICG in all parts of the 
bladder with emphasis on the center and connective tissue bands. 
In the upper parts emitted fluorescence is as strong as in the lower 
parts. 
Bladder no° 2 
Image shows a considerable homogeneous distribution of ICG in all 
parts of the bladder with emphasis on the bottom and connective 
tissue bands. In the upper parts emitted fluorescence seems 
stronger than in the center, strongest parts in the bottom. 
Bladder no° 3 
Image shows a homogeneous distribution of ICG in all parts of the 
bladder with emphasis on the upper parts and connective tissue 
bands. The margins of the bladder are clearly definable. 
Bladder no° 4 
Image shows a heterogeneous distribution of ICG in the bladder. 
Especially in the center of the bladder, ICG fluoresces quite strong.  
The upper parts are rather omitted as well as the left side. 
 
With Capnopen®, the distribution of the emitted fluorescence light is reasonably 
uniform with focus on certain areas within the bladder. The lines with higher 
brightness levels, which run through the bladder, correlate with fibrous connective 
tissue. This becomes apparent especially in the image of bladder no° 4. No 
essential difference in the brightness level between the upper and the lower parts 
of the bladders can be observed. 
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Description of Fluorescence Imaging with Prototype4 
In the images 5 – 8, the bladders sprayed with the Prototype4 are shown. The upper part 
indicates the neck of the bladder. In all four bladders, ICG fluorescence emission is 
apparent. 
Figure 16: Photo documentation of ICG-sprinkled bladders with the Prototype4 
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Table 9: Characteristics of ICG aerosolized bladders (Prototype4) 
 Characteristics 
Bladder no° 5 
In general, signal level is very high. All edges of the bladder are 
clearly definable. 
Image shows a considerable homogeneous distribution of ICG in 
all parts of the bladder with emphasis on the upper parts and 
connective tissue bands. 
Bladder no° 6 
In general, signal level is moderate. Clearly definable edges on the 
left side, vague edges on the right side. 
Image shows a considerable homogeneous distribution of ICG in 
all parts of the bladder with emphasis on the lower parts and 
connective tissue bands. 
Bladder no° 7 
Signal level differs from intense (lower parts) to weak (upper 
parts). Edges of the bladder are not always clearly definable. 
Image shows a significantly higher fluorescence in the lower parts. 
As a straightly drawn and sharp border between the different signal 
levels is visible, there might have occurred some technical 
problems with the IC-View Camera. 
Bladder no° 8 
In general, recorded fluorescence power is satisfactory. Edges of 
the bladder are not always clearly definable. 
Image shows a spotted distribution of ICG in all parts of the bladder 
with emphasis on the lower parts. 
Comparison between Capnopen® and Prototype4 
Common ground in the experiments of both nebulizers is the emission of 
fluorescence light in all parts of the respective bladders. There are no parts within 
the bladder without any accumulation of ICG.  
However, differences exist regarding the signal intensity level. In the images of 
the Capnopen®, the distribution pattern of the fluorescent ICG is very 
homogenous with similar signal intensity levels. Compared to that, in the images 
of Prototype4, signal intensity levels vary from intense (bladder no. 5), modest 
(bladder no. 6) to low (bladders no. 7&8). 
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3.3.3 Distribution experiments with DAPI (microscopy) 
For each of both Capnopen® generations, penetration depth measurements in 
three regions (top, middle, low) of the bladders were performed, using 
fluorescence microscopy in order to detect the DAPI stained cell cores. The ideal 
objective of 54 measurements for each region (3 bladders x 2 tissue samples x 3 
images x 3 measurements) was achieved once (Prototype4/Low). In the other 
cases, between 21 (Capnopen®/Low) and 48 (Prototype4/Middle) were 
performed. Reasons for missing measurements were difficulties in histological 
preparation, which did not allow precise measurements. 
In the following sections, first the results for the Capnopen® are presented and 
second the results for the Prototype4 followed by a comparison. All following 
diagrams and table are divided into three columns, which represent the top, the 
middle and the low part of each bladder. 
Penetration depths with Capnopen® 
Figure 17: Graphic representation of different penetration depths depending on 
the position in the bladder (Capnopen®) 
The x-axis indicates the regions of measurement within the bladder (top/middle/low). Y-axis 
indicates the penetration depth in micrometer.  
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Bladder no. 1 (red) shows an increasing penetration depth with 144 µm 
(mean)(n=12; median 146; max 178; min 111; stand dev 23) on top, 257 µm 
(mean)(n=15; median 267; max 302; min 184; stand dev 37) in the middle and 
452 µm (mean)(n=6; median 454; max 475; min 428; stand dev 16) in the low 
region.  
Bladder no. 2 (blue) shows an increasing penetration depth with 113 µm 
(mean)(n=9; median 116; max 129; min 98; stand dev 11) on top, 164 µm 
(mean)(n=15; median 164; max 202; min 136; stand dev 20) in the middle and 
812 µm (mean)(n=9; median 801; max 876; min 777; stand dev 30) in the low 
region.  
Bladder no. 3 (grey) shows an increasing penetration depth with 179 µm 
(mean)(n=18; median 173; max 227; min 138; stand dev 33) on top, 257 µm 
(mean)(n=15; median 261; max 302; min 195; stand dev 29) in the middle and 
306 µm (mean)(n=6; median 306; max 348; min 269; stand dev 30) in the low 
region.  
Table 10: Summary of penetration depth results (Capnopen®) 
 Top  Middle Low 
No. of bladders 3 3 3 
No. of measurements 39 45 21 
Minimum 98 136 269 
Maximum 227 302 876 
Mean 153 226 564 
Median 151 243 459 
Standard deviation 37 53 228 
25 Percentile 119 168 338 
50 Percentile 151 243 459 
75 Percentile 175 268 798 
 
Values (minimum – 75 percentile) are indicated in micrometers 
The penetration depth values are always highest in the low part of the bladders. 
This is valid for all relevant statistical parameters such as mean, median, 
minimum, and maximum. However, the related standard deviation is relatively 
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high. Lowest penetration depth is observed in the top part of the bladders. The 
difference between top and middle part is relatively low, whereas the difference 
between middle and low part is much higher.  
Penetration depths with Prototype4  
Bladder no. 5 (red) shows an increasing penetration depth with 473 µm 
(mean)(n=18; median 485; max 587; min 354; stand dev 63) on top, 1128 µm 
(mean)(n=18; median 1129; max 1247; min 752; stand dev 188) in the middle 
and 1045 µm (mean)(n=18; median 1062; max 1206; min 850; stand dev 850) in 
the low region. 
Bladder no. 6 (blue) shows an penetration depth distribution with 633 µm 
(mean)(n=9; median 633; max 752; min 542; stand dev 71) on top, 746 µm 
(mean)(n=18; median 740; max 816; min 664; stand dev 45) in the middle and 
561 µm (mean)(n=18; median 543; max 697; min 407; stand dev 78) in the low 
region.  
Figure 19: Graphic representation of different penetration depths depending on 
the position in the bladder using Prototype4.  Figure 18: Graphic representation of different penetration depths depending on 
the position in the bladder (Prototype4) 
The x-axis indicates the regions of measurement within the bladder (top/middle/low). Y-axis 
indicates the penetration depth in micrometer. 
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Bladder no. 7 (grey) shows an increasing penetration depth with 465 µm 
(mean)(n=15; median 474; max 587; min 303; stand dev 83) on top, 470 µm 
(mean)(n=12; median 465; max 587; min 374; stand dev 62) in the middle and 
646 µm (mean)(n=18; median 579; max 956; min 465; stand dev 166) in the low 
region.  
Table 11: Summary of penetration depth results (Prototype4) 
 Top  Middle Low 
Measurements 42 48 54 
Minimum 303 374 407 
Maximum 752 1247 1206 
Mean 504 791 750 
Median 511 755 644 
Standard deviation 98 259 244 
25 Percentile 436 597 537 
50 Percentile 511 755 644 
75 Percentile 558 959 244 
 
Values (minimum – 75 percentile) are indicated in micrometers 
Comparing the data, certain statements can be made: The minimum increases 
from 303 µm on top to 374 µm in the middle and 407 µm in the low region. The 
maximum also increases in the beginning from 752 µm to 1247 µm and the 
slightly diminishes to 1206 µm in the low region. Both the mean and the median 
have their maximum value of 791 µm (755 respectively) in the middle, followed 
by 750 µm (644 respectively) in the low region. The lowest mean (respectively 
median) can be found on top. The highest standard deviation of 259 µm can be 
observed in the middle, followed by the low part and the top.  
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Comparison between Capnopen® and Prototype4 
The penetration depths of Prototype4 are clearly above those of the Capnopen® 
regardless of the investigated area.  
The most substantial difference between the two pens is observed in the middle 
region of the bladder. There, the Prototype4 achieves penetration depth values 
comparable to those in the low region. In comparison, the Capnopen® shows a 
highly different penetration depth for the middle and low region. 
The standard deviation in general is much higher for the Prototype4 compared 
with the Capnopen®, especially in the middle region.  
 
Figure 20: Penetration depths of Capnopen®/Prototype4 sorted by regions 
The different penetration depths into inverted bladder serosal tissue after aerosolizing with the 
Capnopen® (identified by the blue box plots) and the Prototype4 (red box plots) are shown. X-
axis indicates the regions of measurement within the bladder. Y-axis indicates the penetration 
depth in micrometer. 
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3.3.4 Distribution experiments with Cisplatin (tissue concentration) 
In three experiments, 27 tissue concentration measurements in three regions (9 
top, 9 middle, 9 low) of the bladders. 
Table 12: Summary of tissue concentration results  
 Top  Middle Low 
Measurements 9 9 9 
Minimum 80 200 160 
Maximum 660 1430 1400 
Mean 295 580 968 
Median 230 430 1060 
Standard deviation 171 398 356 
25 Percentile 188 300 817 
50 Percentile 230 430 1060 
75 Percentile 390 855 1173 
 
Values (minimum – 75 percentile) are indicated in nanograms per milliliter. 
Figure 21: Tissue concentration of Cisplatin sorted by regions (Capnopen®) 
The x-axis indicates the regions of measurement within the bladder (top/middle/low). Y-axis 
indicates the tissue concentration in nanogram per milliliter. 
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The table shows a mean tissue concentration of cisplatin with 295 ng/ml 
(mean)(n=9; median 230; max 660; min 80; stand dev 171) on top, 580 ng/ml 
(mean)(n=9; median 430; max 1430; min 200; stand dev 398) in the middle and 
968 ng/ml (mean)(n=9; median 430; max 140; min 160; stand dev 356) in the low 
region. 
Comparing the data, certain statements can be made: The minimum increases 
from 80 µm on top to 200 µm in the middle and diminishes to 160 µm in the low 
region. The maximum also increases in the beginning from 660 µm to 1430 µm 
and then slightly diminishes to 1400 µm in the low region. Both the mean and the 
median have their maximum value of 968 µm (1060 respectively) in the low part, 
followed by 580 µm (430 respectively) in the low region. The lowest mean 
(respectively median) can be found on top. The highest standard deviation of 259 
µm can be observed in the middle, followed by the low part and the top.  
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4 Discussion 
In this chapter, the results for the central scientific questions are presented. First, 
the new inverted bovine urinary bladder model is discussed. Second, the new 
investigation methods for the transient aerosol formation and spray propagation 
during the injection phase are discussed. This is followed by the discussion of the 
aerosol distribution pattern and tissue penetration depth achieved for the two 
tested nebulizer (Capnopen® and Prototype4). 
4.1 Development and validations of preclinical models 
4.1.1 Inverted bovine bladder model: characteristics and advantages 
over existing preclinical models 
For further technical development of the PIPAC technology, preclinical models 
are needed to investigate and improve the physico-chemical characteristics of 
the injected aerosol. The advantages and disadvantages of experimental 
approaches for the optimization of the pressurized aerosol including the new 
inverted bovine urinary bladder model have been recently published (Schnelle et 
al., 2017). 
Up to now, experimental investigation of the distribution pattern of an aerosol has 
been performed in various models. These PIPAC models included studies ex vivo 
(Solass et al., 2012a, Khosrawipour et al., 2016a, Khosrawipour et al., 2016b), in 
vivo (Solass et al., 2012b) and postmortem (Khosrawipour et al., 2016c). Yet, 
these experimental models suffered from either technical or anatomical 
limitations. For example, the in-vivo swine model (Solass et al., 2012a) had a lack 
of easy reproducibility and handling and was expensive. The plastic container 
model (Khosrawipour et al., 2016a) did not match the requirements of a model, 
which mimics the characteristics of the abdominal cavity. The droplets of the 
aerosol deposited on the plastic walls of the model and then drained down to the 
bottom of the box due to gravitational forces and lack of absorption. This 
inadequacy can be avoided by the walls of the bovine organ, which are able to 
absorb the applied aerosol. 
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The requirements for an experimental model, which comes very close to the 
properties of the abdominal cavity, are multiform. For example, the model should 
be lined completely with serosa, have an oval shape, and contain a volume 
similar to the abdominal cavity. Furthermore, it should be easy in handling, 
reproducible and the cost-effective. Additionally, it should allow pharmacological 
and histological analysis. All these parameters apply for the inverted bovine 
urinary bladder.  
The inverted bovine urinary bladder is a new ex-vivo model, in which the physic-
chemical properties of the injected aerosol can be investigated and improved 
effectively. 
The following main effects can be evaluated by the inverted bovine bladder 
model: 
 
 Penetration depth and drug concentration of the therapeutic aerosol within the 
serosal tissue and the possibility of histological sampling. As inversion of the 
urinary bladder can be achieved very easily (through a small incision in the 
bladder neck, the bladder can be inverted), this ex vivo model offers the 
opportunity of evaluating the target effect of a therapeutic substance onto the 
mucosa (normal, not inverted state) and the serosa (inverted state).  
 
 Homogeneity of aerosol distribution via various experiments: Staining of 
serosa with methylene blue and ICG Fluorescence Imaging. 
 
 Differences in the effects of various therapeutic substances (DAPI, methylene 
blue, ICG, Cisplatin, Doxorubicin): pharmacodynamic studies can be carried 
out with the inverted bovine urinary bladder 
 
 Optimization of the physico-chemical parameters of the operating 
environment: influence of pressure, temperature and electrostatic charges.  
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Table 13: Characteristics of different experimental approaches for pressurized 
aerosol optimization  
 In-vivo large 
animal model 
Tissue fragments 
in a plastic 
container 
Ex-vivo inverted 
bovine urinary 
bladder 
Living animal 
needed 
✔ x x 
Costs High Low Low 
Role of anatomical 
factors and 
vascularization 
Considered Not considered Not considered 
Adequacy of the 
parietal surfaces 
Excellent Poor Good 
Handling Cumbersome Moderately easy Easy 
Reproducibility Moderate High High 
Evaluation of 
technical factors 
Difficult Easy Easy 
 
Overview of advantages and disadvantages of different experimental approaches for pressurized 
aerosol optimization (Schnelle et al., 2017). 
The ex-vivo inverted bovine urinary bladder combines the advantages of the in 
vivo animal model (high adequacy of the parietal surfaces) and the tissue 
fragments containing plastic container (low costs, easy handling and 
reproducibility, easy evaluation of technical factors and the absence of living 
animals). 
There are various possibilities to further develop the method. A further series of 
experiments should be performed in a temperature level of 37°C. Additionally, 
electrostatic charges could be applied to investigate their influence on spray 
propagation and aerosol precipitation. The amount of deposited aerosol, which 
does not penetrate into the serosal tissue, could be weighted to obtain the exact 
degree of penetration.  
4.1.2 Inverted bovine bladder model: limitations 
Technical limitations appeared during the performing of the series of 
experiments. Some of the provided urinary bladders partly differed in diameter, 
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consistence, prestretching and width of neck aperture. Thus, bladders, which 
deviated to much from average had to be sorted out to ensure similar anatomical 
condition in all series of experiments.   
Still, there are also certain issues, which have not been considered in this model, 
but are important to look at. The abdominal cavity is marked by various 
anatomical characteristics, which influence the distribution of a therapeutic 
aerosol significantly. There are regions, such as the spaces between neighboring 
bowel loops for example, which are hidden and not accessible easily by the 
aerosol, although the established capnoperitoneum leads to the formation of an 
arched abdominal cavity. These anatomical circumstances are not taken into 
account in the inverted bovine urinary bladder model. 
4.1.3 Thermographic Imaging model 
Classical field of applied Thermographic Imaging in medicinal context is the 
diagnosis of peripheral vascular diseases, skin, and breast cancer (Gurjarpadhye 
et al., 2015, Ring and Ammer, 2012). 
So far, the Thermographic Imaging method has not been applied for scientific 
investigation of the distribution process in PIPAC research. In principle, the 
advantages of this method are multiform: the possibility of presenting the aerosol 
spreading process during injection phase and the droplet deposition during 
exposure phase in real-time. Furthermore, this technique is simple in handling, 
reproducible and cost-effective.  
Special interest must be put in the real-time measurement. In all models 
published describing the aerosol distribution pattern (Solass et al., 2012b, 
Khosrawipour et al., 2016a, Khosrawipour et al., 2016b), only the result of 
application, as determined by tissue concentration, penetration depth and visual 
examination of stained serosa at the end of the period of exposition, was 
measured. Obviously, this has been a serious limitation, since aerosol distribution 
within a certain space is not static, but is subject to continuous changes. For 
example, due to gravitation forces, any aerosol regardless of optimal droplet size 
will deposit on the ground of the experiment model after a given period of time. 
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The Thermographic Imaging method is supposed to overcome this significant 
limitation by providing a continuous real-time analysis of the distribution pattern.  
There are still limitations, the Thermographic Imaging model is suffering from. 
First, the injection period (30sec) does not correspond to the duration in the 
operational setting (180sec) due to the special modalities of the experimental 
model box. Steady state conditions regarding heat transmission are attained after 
30 sec. 
Second, the exposure phase is not recorded due to technical limitations of the 
model box. A thermographic representation of the distribution behavior of the 
injected aerosol after the injection phase would be desirable to gain information 
about the sedimentation rate of the aerosol droplets over time. The materials 
used for the model box do not allow absorption of the aerosol droplets. Thus, it is 
inevitable that in the process of time, droplets form on the walls and the plastic 
wrap making longer observation of distribution behavior impossible. The 
deposited droplets on the front of the model box distort the received heat 
transmission, as the areas situated behind the droplets cannot be plotted 
representatively anymore. For this reason, the available experiment has high 
significance in analyzing both the spraying behavior of the examined Capnopen® 
and the aerosol distribution pattern during injection phase, but limitations in the 
examination of the absorption phase. A possible new approach to investigate the 
distribution pattern of an injected aerosol in the exposure phase over time would 
be to spray a contrast medium containing aerosol first into a model box and 
consecutively into the bladder model, which are located in a computed 
tomography scanner. In predefined time intervals, computed tomographic images 
should be taken with the aim of extrapolating from the density of the contrast 
medium in each spot in space to the distribution pattern of the exposed aerosol. 
Third, the color (indicating amount of heat transmission) does not allow to draw 
explicit conclusions of the absolute concentration of the aerosol. Although there 
is a clear correlation between color and aerosol amount, it remains unclear, 
whether this correlation is proportional or not. For example, the red areas 
indicate, that the heat transmission is not disturbed by any aerosol droplets. After 
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beginning the injection, the area in the center of the box quickly turns yellow 
indicating less heat transmission caused by the appearance of aerosol droplets. 
Yet, one cannot draw any conclusion, whether just a very small number of 
droplets leads to the color change or a respectable amount is needed. The same 
issue appears later in the experiment. The color “blue” represents an enormous 
reduction of heat transmission. Again, it remains uncertain, how many droplets 
are responsible for the cooling of the area. Even a further concentration of aerosol 
might not lead to a significant change in heat transmission. To sum up, the 
available experiment points up relative changes in the heat transmission without 
making clear statements about the exact absolute amount of the distributed 
aerosol over time.  
4.2 Evaluation of a next-generation medical device 
To my knowledge, this dissertation is the first to deal with the comparison of 
distribution behavior of a drug containing solution in an experimental model 
between the Capnopen®, currently used as a standard in the operational setting, 
and the Prototype4, the newest generation. As an experimental model, the 
inverted bovine urinary bladder has been proved to be a valid possibility to mimic 
the abdominal cavity.  
The proposed core element of effective PIPAC therapy is a homogenous drug 
distribution. Only through that, it can be guaranteed, that the drug (here in the 
experiments Methylene blue, ICG, DAPI and Cisplatin) can reach all target cells 
and unfold its full efficacy. As long as not all regions of the abdominal cavity (or 
as an experimental model the inverted bovine urinary bladder) are sufficiently 
covered with the drug containing solution, no effective or even curative 
therapeutic approach will be possible.  
 
In a large series of experiments, two different medical devices (Capnopen® and 
Prototype4) were tested to carve out the granulometric aerosol characteristics,  
the spray propagation behaviour and the distribution and penetration pattern. As 
distribution within the abdominal cavity is still not ideal, the hypothesis was, that 
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a new medical device (Prototype4) with improved technical properties would lead 
to a more homogenous distribution.  
In a first step, technical properties are revealed through granulometric and 
thermographic analysis. 
4.2.1 Granulometric analysis 
Granulometric analysis via Laser Diffraction to determine the droplet size 
distribution offers a good possibility to gain further information about the aerosol 
characteristics of both Capnopen®.  
Two main aspects can be examined by means of the obtained granulometric 
data. First, the aerosol of Prototype4 is slightly more homogenous regarding 
droplet size distribution then of Capnopen®. Second, the range of droplet size 
diameters of both Capnopen® is comparatively small. 80 % of the entire aerosol 
volume consists of droplets with comparably similar size. Through that, the 
objective of a low dispersion of droplet diameters within the aerosol has become 
closer. This is beneficial for both less aerosol volume loss due to inertial impaction 
and a higher homogeneity within the aerosol. These characteristics rather apply 
for the aerosol of Prototype4 than for the Capnopen®.  
In current research, there is discussion about the ideal droplet size for optimal 
homogenous drug distribution and effective penetration into the tissue. Various 
granulometric experiments have been carried out to define the current diameter 
distribution of the nebulizer. Khosrawipour et al described, that the Capnopen® 
sprays with a droplet diameter ranging from 3 – 15 µm (Khosrawipour et al., 
2016a). In the granulometric analysis, Göhler et al revealed, that the size 
distribution is bimodal with one peak <3 µm and the other 10 – 15 µm. Similar 
results were achieved by another study (Reymond and Solass, 2014).  
The findings in the present granulometric experiment are difficult to compare with 
the granulometric analysis of Göhler et al., as in their study, a completely different 
experimental set up had been established (different angioinjector, laser - 
diffraction spectrometer and a shorter distance between nozzle of the nebulizer 
to the laser beam) (Gohler et al., 2017). 
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4.2.2 Injection angle and distribution velocity 
The performed series of experiments in the Thermographic Imaging model reveal 
certain advantages of the Prototype4 over the established Capnopen® regarding 
injection angle and aerosol velocity distribution.  
First, the injection angle of the nozzle of the Prototype4 is wider with β=55°. 
Through this technical characteristic, the injection jet is not only restricted to the 
central column of the box, but leads to a wider, more scattered distribution of the 
aerosol volume in space, so that the inertial impaction factor opposite to the 
nebulizer nozzle is less distinctive and more homogenous drug distribution can 
be achieved. 
Second, the spreading of aerosol proceeds faster. Therefore, the model box is 
filled adequately earlier leading to a longer exposure phase.  
In general, the spreading pattern of both devices is similar. The injection of the 
aerosol leads to a symmetrical distribution within the box. The process of filling 
runs of with coverage of the center of bottom first, followed by the entire ground 
and then moving progressively upwards, until the entire box is filled at the end of 
the thermographic recording. The upper central parts are aerosolized last. Both 
Capnopen® achieve sufficient filling with aerosol of the entire box after a 
predefined period. 
4.2.3 Visual examination of distribution pattern 
Methylene blue staining within the inverted bovine urinary bladder was the first 
distribution pattern analysis. Visual-qualitative examination revealed a 
considerable homogenous staining of the surfaces of the bladders with no 
substantial difference between the Capnopen® and the Prototype4. The obtained 
results are of limited value, as qualitative analysis via visual examination leaves 
a big margin in interpretation. Additionally, for Prototype4, only one experiment 
round was performed. Hence, these series of experiments served as proof of 
model concept only. By means of the methylene blue staining, the feasibility of 
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the experimental set up of the inverted bovine urinary bladder was tested 
successfully. 
In the results of the Fluorescence Imaging method, no fundamental differences 
between the Capnopen® regarding the visual distribution pattern of ICG can be 
seen. All parts of the inverted bovine urinary bladders, independently from the 
used Capnopen®, are covered with ICG emitted fluorescence. The images of the 
Capnopen® even show a slightly more homogenous emission in comparison to 
Prototype4.  
It is self-explanatory, that all parts of the bladders emitting ICG fluorescence light, 
must have been covered with the aerosol during the exposure time of 30 min. 
Yet, the recorded fluorescence light does not make any statement about the 
period of aerosol presence in the respective parts of the bladders, nor does it let 
extrapolate from the signal intensity level to the penetration depth into the serosal 
tissue. As only the emission of the tissue surface is recorded, deeper penetration 
does not result in more intense signal intensity level.  This on-off principle limits 
the informative value of this method. 
Another point of interest was to compare not only the differences in the 
fluorescence images between the two Capnopen®, but also to combine their 
distribution information with the results of the obtained results from the DAPI 
penetration depth measurements and evaluate if a positive correlation can be 
carved out.  
Unfortunately, a direct connection between these two methods cannot be 
determined. In the analyses of fluorescence microscopy, the obtained penetration 
depth results of DAPI reveal a substantial increase in the respective low parts of 
the bladders. Furthermore, in general, the penetration depth values are higher 
with the Prototype4 than with the Capnopen®.  These findings cannot be 
validated by the ICG fluorescence imaging method.  
The ICG fluorescence imaging method suits for getting a first visual insight into 
the drug distribution pattern within the bladder, but lacks in analyzing the concrete 
penetration depth into tissue.   
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4.2.4 Penetration depths in inverted bovine urinary bladder model 
The experiments, evaluating the penetration depth of DAPI into the serosal tissue 
of the inverted bovine urinary bladder, have revealed major differences between 
the Capnopen® and Prototype4. The penetration depths of Prototype4 created 
aerosols are clearly above those of the Capnopen® regardless of the investigated 
area.  
Up to now, penetration depth investigations in different locations within an 
experimental model had always been disappointing showing unequal penetration 
depth values in the different regions. Even though these preclinical models 
suffered from various inadequacies, it is clear, that improvement towards a 
homogeneous distribution of penetration depth is necessary in the development 
of PIPAC technology.  
Different aspects of the penetration depth measurements should be taken into 
consideration.  
In scientific literature, only few penetration depth values of PIPAC technology are 
indicated. In tissue measurement of a postmortem swine model, the penetration 
depth of doxorubicin was found out to be up to 350 µm opposite of the nozzle of 
the nebulizer and remarkably lower in more distant corners of the abdominal 
cavity (Khosrawipour et al., 2016c). Solass et al reported a penetration depth of 
500 – 600 µm into tumor and peritoneal tissue (Solass et al., 2014). Preclinical 
experiments using a plastic box with positioned tissue samples in predefined 
areas also showed a substantial difference in the penetration depth values 
depending on the location of the specimen. Only the samples situated closely to 
the nozzle of the nebulizer had a mean penetration depth of 200 - 300 µm, rapidly 
dropping under 100 µm on the sides and the top of the plastic box (Khosrawipour 
et al., 2016a).  
For Capnopen®, median penetration depth values are 151, 243 and 459 µm for 
top, middle, and low region respectively. Overall, considering the values in an 
absolute manner, these values correspond to the findings the earlier published 
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studies. The median of 459 µm for the low region is comparable to the result of 
Solass et al of 500 – 600 µm, which reported doxorubicin penetration however. 
Yet, differences exist regarding the values of the upper and lower part of the 
bladders. In the other studies, penetration depth values of more distant location 
to the spray jet were reported to be significantly lower than the maximum opposite 
of the nozzle. Here, the median values of 151 µm in the top and 243 µm in the 
middle are also lower, but do not fall below the limit of 100µm.  
For the new Prototype4, penetration depth values differ substantially from the 
previous findings in PIPAC research. Both the absolute values and the 
differences between the top, middle and low part values indicate an improved 
distribution pattern.  
With a median value of 511 µm for the top region, the penetration depth is 
significantly higher. Also, the values of the middle and the low region of 755 and 
644 µm respectively show a deeper penetration into the serosal tissue than both 
with the Capnopen® in the present experiments and in the other studies reported.  
These findings can be explained by the improved characteristics of the aerosol 
created by the Prototype4 and the advantages of the new inverted bovine urinary 
bladder. In the analysis of the new Prototype4, the Thermographic Imaging 
analysis points out a wider injection angle of the nozzle and an increased velocity 
of aerosol propagation. The granulometric evaluation of droplet size distribution 
via Laser Diffraction reveals a more homogenous aerosol regarding droplet size 
distribution. Thus, these developed technical and granulometric characteristics of 
the aerosol created by the Prototype4 lead to an improved drug distribution 
pattern and consecutively, as explained in the following, to a deeper drug 
penetration into the serosal tissue. 
Correlation between penetration depth and distribution pattern 
There are two basic assumptions, which contribute to the understanding of the 
relation between penetration depth and distribution pattern.  
First, the higher the concentration of a drug is in a certain area of the experimental 
model, the deeper it penetrates the tissue. 
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Second, the longer the exposure time, the deeper the penetration. Granted that 
the aerosol has distributed gas-like first, but then its droplets deposit on the 
ground after a short period, a reduced penetration depth in the upper parts and 
an increased in the lower parts will be the consequence.  
Based on these two assumptions, one can extrapolate from the penetration depth 
to the distribution pattern of an aerosol.  
A third mechanism of an elevated penetration depth must be noted. In the stream 
jet of the Capnopen®, the inertial impaction of the aerosol contributes to a higher 
penetration depth (Gohler et al., 2016). This just affects the region of the bladder 
opposite of the Capnopen® nozzle.  
In a series of experiments, the penetration depth of DAPI into the tissue, 
aerosolized by Capnopen® and Prototype4, was investigated. The detailed listing 
of the penetration depth values can be found in the chapter “results”. The results 
reveal an uneven penetration depths distribution with highest values in the low 
part of the bladder. This is not too surprising due the fact, that after a certain 
period of time, the droplets deposit on the ground of the bladder due to gravitation 
forces. Furthermore, this region is located in the stream jets of both Capnopen®, 
so that during injection period, penetration into the tissue is be supported by 
inertial impaction (Gohler et al., 2016).  
Yet, considerable differences between the penetration depth values of both 
Capnopen® can be recognized. For the Capnopen®, a clear discrepancy 
between the middle and the top parts on the one hand and the low part on the 
other hand can be identified regarding homogenous penetration depth 
distribution. These penetration depths can be interpreted as characteristics of the 
distribution pattern. As described above, deep penetration is caused by a high 
amount of drug in the particular space and a long exposure time.  
By means of these considerations, one can draw the conclusion, that with the 
Capnopen®, the distribution pattern of DAPI within the inverted bovine urinary 
bladder is not homogenous, but heterogenous with focus on the bottom. Similar 
results regarding heterogenous drug distribution have already been published 
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(Khosrawipour et al., 2016a, Khosrawipour et al., 2016b, Khosrawipour et al., 
2016c). 
The penetration depths of Prototype4 are clearly above those of the Capnopen® 
regardless of the investigated area. Furthermore, the achieved penetration depth 
values in the middle come very close to those in the low part.  
These values indicate an improved spatial drug distribution. Even in the top part 
of the bladder, a higher concentration of the aerosol seems to be established, 
leading to a higher penetration depth.  
Compared to the distribution pattern of the Capnopen®, it can be clearly 
determined, that the distribution with Prototype4 is more homogenous.  
Yet, it must be outlined, that for these statistical analyses, only three bladder 
experiments for each Capnopen® were carried out. Therefore, the results of the 
penetration depth distribution must be interpreted with caution. Further studies 
are necessary to confirm the superior qualities of the Prototype4. 
4.3 Conclusion 
Through various series of experiments (Methylene Blue staining, ICG/DAPI and 
Cisplatin injection), the inverted bovine urinary bladder model has been 
implemented successfully and regarded valid for further application. Results were 
reproducible and convincing.  
In the further method development, different options appear legitimate. 
Electrodes could be placed on top and bottom. Through applying a voltage, the 
modified distribution pattern of the administered aerosol could be examined. This 
technique has been described before by Kakchekeeva et al (Kakchekeeva et al., 
2016).  
Another field of necessary further research is the presentation of the transient 
aerosol behavior in space over time. The Thermographic Imaging method has 
been shown to be able to present the aerosol injection phase in a model box in 
real-time. However, marks only first step in this important investigation field, as 
both the model (plastic box) and the passage of recording (only injection phase) 
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are not ideal yet. The more informative exposure phase could not be displayed 
due to technical restrictions. Therefore, either these limitations can be overcome 
or a new fundamental approach is needed. This could be for example the use of 
Computed-tomographic (CT) Imaging. The inverted bovine urinary bladder model 
could be placed in the CT. The distribution pattern of the aerosol, consisting of 
contrast medium, over time could be displayed by taking repeated CT scans in 
predefined time intervals.  
The research results suggest a superior distribution pattern of the aerosol created 
by Prototype4. This could be confirmed by Thermographic Imaging, penetration 
depth measurements of DAPI in the inverted bovine urinary bladder. Yet, a 
completely homogenous drug distribution could not be described, there are still 
differences between the upper and the lower regions in the respective models. 
One key element in the creation process of PIPAC technology is the nebulizer. 
The way, the drug containing solution is atomized into the aerosol decides upon 
the further distribution and subsequently penetration into tissue. In the presented 
series of experiments, aerosols, created by the Prototype4, had superior qualities 
regarding injection angle, spreading velocity, droplet size diameter homogeneity 
and approximating penetration depth values between the top and bottom regions. 
These findings should now be further evaluated in improved settings 
(environmental steering) and taken into account in the further technical 
development of the next Capnopen®. 
Particular interest should be put in the steering of the environment. As already 
described in the introduction, there are two main paths, which are considered 
equally important in the creation process of the aerosol. Only if the technical 
devices and the drug containing solution are accurately coordinated, the 
administered aerosol will diffuse and penetrate the target tissue effectively. In this 
dissertation, focus has been put on the evaluation of the different generation of 
the Capnopen®. In further experiments, the impact of modified physico-chemical 
factors such as temperature, pressure and loading should be examined.  
Various limiting factors in the experiment conception appeared during experiment 
implementations. In the inverted bovine urinary bladder experiments, a wide 
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variation of anomalies in the anatomy of the used bladders impeded the creation 
of exact comparable experimental set ups. It is natural, that no bovine urinary 
bladder is exact like the other. However, only bladders with comparable 
characteristics regarding diameter, consistence, prestretching and width of neck 
aperture were used. 
In the ICG/DAPI series of experiments, for each of both Capnopen®, four 
bladders were investigated, in the Cisplatin experiments, three bladders only with 
Capnopen®. More series of experiments are now needed to confirm first obtained 
promising results.  
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5 Abstract 
For a long time, PM has been considered to be a terminal clinical condition. 
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an innovative 
therapeutic approach with the target to become a curative treatment. The 
chemotherapeutic drugs are not delivered anymore into the abdominal cavity by 
conventional lavage, but administered by means of a pressurized, 
chemotherapeutic drug containing aerosol. The objective is to achieve a 
homogeneous drug distribution within the abdominal cavity. Through the gaseous 
propagation of the chemotherapeutic drugs, every region, regardless of its 
proximity or distance to the nozzle of the nebulizer in the laparoscopic setting, is 
covered sufficiently. This is not attainable with conventional lavage, where the 
low abdominal regions are treated sufficiently due to gravitational forces, while 
the upper regions are less covered, resulting in ineffective cancer treatment, as 
not all tumor nodules are caught.  
In the past, various in vivo, ex vivo and postmortem swine experiments have been 
made to describe and improve the distribution pattern of an injected aerosol and 
the penetration depth into the serosal tissue. However, theoretical considerations 
regarding homogenous drug distribution via aerosolized administration did not 
match with actual results. Drug propagation was found out to be heterogeneous. 
All presented models suffer from different limitations, such as difficult 
reproducibility of results, extensive costs, and high discrepancies between 
anatomical conditions and model setup. Therefore, in this dissertation, a new ex 
vivo preclinical model, the inverted bovine urinary bladder, has been introduced. 
Advantages of the inverted bovine urinary bladder include simple handling, cost 
effectiveness, effect evaluation of various substances both on the mucosa and 
the serosa, integration of the physico-chemical characteristics of the operational 
environment, and proximity to the abdominal anatomical conditions.  
Additionally, so far, no model is able to cover the transient behavior of spray 
propagation. Therefore, a first dynamic experimental model, the Thermographic 
Imaging, has been established to describe the aerosol propagation within a model 
box during the injection period in real time. The presented Thermographic 
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Imaging model is able to characterize the spraying behavior of the inserted 
different nebulizers and the aerosol propagation behavior during injection phase, 
but due to technical restrictions is not applicable to the sedimentation process of 
the aerosol during the exposure period.  
A further focus of this dissertation is the implementation of a series of 
experiments, in which aerosols are created via two different nebulizers 
(Capnopen® and Prototype4) and and their distribution/penetration depth pattern 
is evaluated in these new established models. 
First, a visual-qualitative proof of drug distribution in all parts of the bladder was 
conducted, observing the effect of injected dye methylene blue and ICG. This 
was enhanced with penetration depth measurements of injected DAPI in three 
predefined regions within the urinary bladder. Obtained data revealed relevant 
differences not only between the three different regions, but also between the 
investigated two Capnopen® types. The Prototype4 achieved superior 
penetration depth in total and a more homogenous distribution. In a third step, 
cisplatin, one of the chemotherapeutic drugs used in PIPAC technology, was 
aerosolized and tissue concentration in the same three locations measured. 
Obtained data confirm the findings of DAPI penetration depth measurements.  
These series of experiments show impressively the need of optimizing both the 
technical, physical, and pharmacodynamic characteristics of the injected aerosol 
and the distribution pattern. The aerosol characteristics of the Prototype4 are 
superior in many ways. The combination of improved injection, more 
homogenous droplet size range, higher and more equally distributed penetration 
depth values and tissue concentration underlines the achieved aerosol 
improvement.  
The inverted bovine urinary bladder turns out to be a valid model for the 
evaluation of the distribution pattern and penetration depth in the serosal tissue. 
In the future, these obtained promising results from the preclinical models should 
be transferred to the clinical operational setting.  
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6 Zusammenfassung (Deutsch) 
Peritonealkarzinose wurde lange Zeit als klinischer Endzustand mit infauster 
Prognose angesehen. Druck-Aerosol-Chemotherapie (PIPAC) ist ein innovativer 
therapeutischer Ansatz mit der Zielsetzung, eine kurative Behandlungsform bei 
Peritonealkarzinose zu werden. Die chemotherapeutischen Wirkstoffe werden 
nicht mehr durch eine konventionelle Spülung in die Bauchhöhle, sondern mittels 
eines unter Druck stehenden, chemotherapeutisches Arzneimittel enthaltenden 
Aerosols eingebracht. Ziel ist es, eine homogene Medikamentenverteilung in der 
Bauchhöhle zu erreichen. Durch das gasförmige Verteilungsverhalten der 
Chemotherapeutika wird sollte jeder Bereich, unabhängig von seiner Entfernung 
zur Einspritzdüse, während der Laparoskopie ausreichend abgedeckt werden. 
Dies ist mit konventioneller Lavage nicht erreichbar, bei der die unteren 
Bauchbereiche aufgrund der Schwerkraft ausreichend behandelt werden, 
während die oberen Regionen weniger bedeckt sind, was zu einer ineffektiven 
Krebsbehandlung führt. 
 
In der Vergangenheit wurden verschiedene In-vivo-, Ex-Vivo- und Postmortem-
Schweine-Experimente durchgeführt, um das Verteilungsverhalten eines 
injizierten Aerosols und die Eindringtiefe in das Serosagewebe zu beschreiben 
und zu verbessern. Theoretische Überlegungen zur homogenen Verteilung von 
Medikamenten mittels Aerosolapplikation stimmten jedoch nicht mit den 
tatsächlichen Ergebnissen überein. Die Ausbreitung von Medikamenten erwies 
sich als heterogen. Alle vorgestellten Modelle unterliegen unterschiedlichen 
Einschränkungen, wie z. B. die schwierige Reproduzierbarkeit der Ergebnisse, 
hohe Kosten und hohe Diskrepanzen zwischen anatomischen Bedingungen und 
Modellaufbau. Daher wurde in dieser Dissertation ein neues präklinisches Ex-
vivo-Modell, die invertierte Rinderharnblase, eingeführt. Die Vorteile dieses 
neuen Harnblasenmodells sind die einfache Handhabung, die Kosteneffizienz, 
die Untersuchung verschiedener Substanzen sowohl auf der Mukosa als auch 
auf der Serosa, die Möglichkeit einer Einbeziehung der physikalisch-chemischen 
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Eigenschaften der Operationsumgebung und die ähnlichen anatomischen 
Bedingungen zu denen eines menschlichen Abdomens. 
 
Darüber hinaus kann bisher kein Modell das vorübergehende 
Ausbreitungsverhalten eines Aerosols in der Injektionsphase abdecken. Daher 
wurde ein erstes dynamisches Versuchsmodell, das Thermographic Imaging, 
entwickelt, um die Ausbreitung des Aerosols in einer Modellbox während der 
Injektionszeit in Echtzeit zu beschreiben. Das vorgestellte Thermographic 
Imaging Modell ist in der Lage, das Sprühverhalten der eingesetzten 
unterschiedlichen Vernebler und das Ausbreitungsverhalten von Aerosolen 
während der Injektionsphase darzustellen. Aufgrund technischer 
Einschränkungen ist es jedoch nicht auf den Sedimentationsprozess des 
Aerosols während der Expositionszeit anwendbar. 
 
Zunächst wurde ein visuell-qualitativer Nachweis der Medikamentenverteilung in 
allen Teilen der Blase durchgeführt, wobei die Wirkung des injizierten Farbstoffs 
Methylenblau und ICG beobachtet wurde. Durch Messungen der Eindringtiefe 
von injiziertem DAPI in drei vordefinierten Bereichen der Harnblase wurden diese 
ersten Eindrücke objektivierbar gemacht. Die gewonnenen Daten zeigten 
relevante Unterschiede nicht nur zwischen den drei verschiedenen Regionen, 
sondern auch zwischen den beiden untersuchten Capnopen®-Typen. Der 
Prototyp4 erreichte insgesamt eine größere Eindringtiefe und eine homogenere 
Verteilung. In einem dritten Schritt wurde Cisplatin, eines der in der PIPAC-
Technologie verwendeten Chemotherapeutika, eingesprüht und die 
Gewebekonzentration an denselben drei Stellen gemessen. Die erhaltenen 
Daten bestätigen die Ergebnisse der DAPI-Eindringtiefenmessungen. 
 
Ein weiteres Hauptaugenmerk dieser Dissertation liegt in der Durchführung von 
mehreren Experimenten, in denen mittels zweier verschiedener Vernebler 
(Capnopen® und Prototype4) Aerosole erzeugt werden, deren 
Verteilungsverhalten beziehungsweise Eindringtiefen in diesen neu erstellten 
Modellen untersucht werden. 
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Diese Versuchsreihen zeigen eindrucksvoll die Notwendigkeit, sowohl die 
technischen, physikalischen als auch die pharmakodynamischen Eigenschaften 
des injizierten Aerosols und das Verteilungsmuster zu optimieren. Die 
Aerosoleigenschaften des Prototype4 sind in vielerlei Hinsicht überlegen.  
Die Kombination aus verbesserter Injektion, homogeneren Tröpfchengrößen, 
größerer und gleichmäßig verteilter Eindringtiefe und Gewebekonzentration 
unterstreicht die erzielte Verbesserung des Aerosols. 
Es hat sich gezeigt, dass die invertierte Rinderharnblase ein valides Modell für 
die Bewertung des Verteilungsmusters und der Eindringtiefe in das 
Serosagewebe darstellt. In der Zukunft sollten diese vielversprechenden 
Ergebnisse aus den präklinischen Modellen in den klinischen Alltag übertragen 
werden. 
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